



UNIVERSITÀ DI PARMA

ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential

This is the peer reviewed version of the following article:

Original

Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential / de la Fuente Revenga, Mario; Fernández Sáez, Nerea; Herrera Arozamena, Clara; Morales García, José A; Alonso Gil, Sandra; Pérez Castillo, Ana; Caignard, Daniel Henri; Rivara, Silvia; Rodríguez Franco, María Isabel. - In: JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0022-2623. - 58:12(2015), pp. 4998-5014. [[10.1021/acs.jmedchem.5b00245](https://doi.org/10.1021/acs.jmedchem.5b00245)]

Availability:

This version is available at: 11381/2795297 since: 2021-10-11T15:14:33Z

Publisher:

American Chemical Society

Published

DOI:[10.1021/acs.jmedchem.5b00245](https://doi.org/10.1021/acs.jmedchem.5b00245)

Terms of use:

Anyone can freely access the full text of works made available as "Open Access". Works made available

Publisher copyright

note finali coverpage

(Article begins on next page)

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of their Neurogenic Potential

Journal:	<i>Journal of Medicinal Chemistry</i>
Manuscript ID:	jm-2015-002458.R2
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	de la Fuente Revenga, Mario; Spanish National Research Council, Instituto de Química Médica Fernández-Sáez, Nerea; Spanish National Research Council, Instituto de Química Médica Herrera-Arozamena, Clara; Spanish National Research Council, Instituto de Química Médica Morales-García, José; Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas (IIB-CSIC), Alonso-Gil, Sandra; Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas (IIB-CSIC), Pérez-Castillo, Ana; Instituto de Investigaciones Biomédicas "Alberto Sols", Consejo Superior de Investigaciones Científicas (IIB-CSIC), Caignard, Daniel; Institut de Recherches Servier, Rivara, Silvia; Università degli Studi di Parma, Dipartimento Farmaceutico Rodríguez-Franco, María Isabel; Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (CSIC), Química Médica I

SCHOLARONE™
Manuscripts

1
2
3 **Novel *N*-Acetyl Bioisosteres of Melatonin: Melatonergic**
4
5 **Receptor Pharmacology, Physicochemical Studies, and**
6
7 **Phenotypic Assessment of their Neurogenic Potential**
8
9

10
11
12 Mario de la Fuente Revenga,[†] Nerea Fernández-Sáez,[†] Clara Herrera-Arozamena,[†]
13 José A. Morales-García,^{‡,§} Sandra Alonso-Gil,^{‡,§} Ana Pérez-Castillo,^{‡,§} Daniel-Henri
14 Caignard,[#] Silvia Rivara,[⊥] and María Isabel Rodríguez-Franco^{*,†}
15
16
17
18
19
20
21

22 [†]Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-
23 CSIC), C/ Juan de la Cierva 3, 28006-Madrid, Spain.
24
25

26 [‡]Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de
27 Investigaciones Científicas (IIB-CSIC), C/Arturo Duperier 4, 28029-Madrid, Spain.
28
29

30 [§]Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
31 (CIBERNED), C/ Valderrebollo 5, 28031-Madrid, Spain.
32
33

34 [#]Institut de Recherches Servier, 125 Chemin de Ronde, 78290-Croissy sur Seine,
35 France.
36
37

38 [⊥]Dipartimento di Farmacia, Università degli Studi di Parma, Parco Area delle Scienze
39 27/A, 43124-Parma (Italy).
40
41
42
43
44
45

46 *Dedicated to our dear colleague Prof. José Elguero on the occasion of his 80th birthday*
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Herein we present a new family of melatonin-based compounds, in which the acetamido group of melatonin has been bioisosterically replaced by a series of reversed amides and azoles, such as oxazole, 1,2,4-oxadiazole and 1,3,4-oxadiazole, as well as other related 5-membered heterocycles, namely 1,3,4-oxadiazol-(thio)ones, 1,3,4-triazol-(thio)ones and an 1,3,4-aminothiadiazole. New compounds were fully characterized at melatonin receptors (MT₁R and MT₂R), and results were rationalized by superimposition studies of their structures to the bioactive conformation of melatonin. We also found that several of these melatonin-based compounds promoted differentiation of rat neural stem cells to a neuronal phenotype *in vitro*, in some cases to a higher extent than melatonin. This unique profile constitutes the starting point for further pharmacological studies to assess the mechanistic pathways, and the relevance of neurogenesis induced by melatonin-related structures.

INTRODUCTION

Melatonin (Figure 1) is a neurohormone produced in different tissues, primarily in the pineal gland, but also in retina and gastrointestinal tract. Beyond its fundamental role in circadian and seasonal rhythms' regulation, melatonin is involved in a variety of physiological processes like the modulation of immune and endogenous antioxidant systems, among others.¹ Due to this wide array of biologically-relevant activities, research efforts aiming to identify new melatonergic analogues increase continuously.²

Two G-protein-coupled receptors (GPCRs), named MT₁ and MT₂ (MT₁R and MT₂R), mediate most of the melatonin physiological and pharmacological actions. These melatonin receptors (MTRs) lack a crystalized structure that could allow the characterization of their tertiary structure and the pattern of interactions undertaken with their ligands. A number of homology models of the MT₁R and MT₂R have been built, although the low identity of their sequences with the used templates increases the speculation degree, thus limiting the utility of these models for drug design purposes.^{2,3} In this regard, ligand-based design of novel melatonergic agents is still widely exploited. This approach has provided three approved melatonergic ligands, besides melatonin itself: agomelatine for major depression, ramelteon for sleep disorders and tasimelteon for non-24-hour sleep-wake disorder (Figure 1), whilst others are in developmental stages.⁴

Subtle and major changes in the structure of melatonin have led to a plethora of ligands, in many cases able to surpass the picomolar affinity of the endogenous agonist. Based on these studies, several pharmacophoric models have been proposed.⁵⁻⁷ Among these pharmacophores, there is a wide consensus about the necessity of an oxygen atom attached to the aromatic or heteroaromatic core connected to the acetamido-containing side chain. Deletion of the methoxy group generally provokes a decrease in intrinsic

activity, like is the case of the antagonist luzindole (Figure 1). Regarding the indole nucleus, there are numerous examples of aromatic scaffold hopping, like agomelatine and other naphthalenic derivatives, which demonstrate that the presence of the indole-NH is not essential for activity.⁸⁻¹⁰ Exploitation of a putative lipophilic pocket close to the binding site of melatonin has led to the development of nonselective and MT₂R-selective ligands,¹¹ and has yielded key pharmacological tools, like luzindole or the radioligand 2-[¹²⁵I]iodomelatonin.¹²⁻¹⁴ Both indole replacement and utilization of the abovementioned non-polar cavity had proven to be successful approaches, although usually resulted in an overall increase of the lipophilicity that generally undermines drug-like properties.¹⁵⁻¹⁷ Therefore, from a drug discovery point of view, it is more desirable to increase the enthalpic component of the binding free-energy (e.g., hydrogen bonds, multipolar and cation- π interactions) via optimization of specific polar interactions.¹⁸




Figure 1. Melatonergic drugs on the market and other selected melatonergic ligands.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reported modifications on the acetamido group of melatonin were discouraging, as generally resulted in a significant decrease, or total loss, of binding affinity and potency at MT₁R and MT₂R. Indeed, there are few described cases of bioisosterism in which the acetamido group has been replaced by other carbamoyl moieties whilst the 5-methoxytryptamine skeleton was kept intact, such as the propyl urea **1**¹⁹ and *N*-(2-(5-methoxy-1*H*-indol-3-yl)ethyl)-2,4-dinitroaniline (ML-23).^{20,21} Piromelatine and its hydroxyl analogue **2** represent examples of atypical acylation of the tryptamine core with a 4*H*-pyran-4-one fragment, able to retain significantly good affinities.²²⁻²⁴ More recently, Rami et al. described the use of 5-membered heterocycles replacing for either the acyl or the whole acetamido group over the structure of agomelatine, generally maintaining good binding affinities for MTRs.²⁵

The acetamido group of melatonin has been proposed to intervene in captodative hydrogen bonds.³ Therefore, its bioisosteric replacement could represent a useful strategy for the structural understanding of the not so well-known properties of the binding pocket of this fragment, in terms of size, shape, electronic distribution and lipophilicity. Exploitation of specific polar interactions occurring in this pocket with acetamido-like moieties may result in a greater enthalpy-driven binding of ligands. Herein, we have replaced the *N*-acetyl fragment of melatonin with a series of reversed unsaturated amides and some well-established amide bioisosteres: oxazole, 1,2,4-oxadiazole and 1,3,4-oxadiazole;²⁶ as well as other related acidic azoles bearing a hydrogen that could intervene in hydrogen bonds: 1,3,4-oxadiazol-(thio)ones, 1,3,4-triazol-(thio)ones and 1,3,4-aminothiazole (Figure 2). On another hand, the naturally occurring alkaloid 5-methoxy-*N,N*-dimethyltryptamine (5-MeO-DMT) that shows high affinity for several serotonin receptor populations,²⁷ is also known to displace 2-[¹²⁵I]iodomelatonin from hamster brain membranes.²⁸ This indoleamine was included in

1
2
3 the study to investigate the ability of its dimethylamino substituent to bind human
4 MTRs. The thermodynamic solubility at pH 7.4 of representative compounds of each
5 family showing significant binding to MTRs was determined. Considering the high
6 degree of similarity in the series, their relative hydrophilic nature was inferred from
7 solubility values. For thoseazole compounds capable of undergoing an acid-base
8 equilibrium, the solubility was also determined at different pH values in order to study
9 their acid or basic character.²⁹
10
11
12
13
14
15
16
17

18
19 Beyond ligand-MTRs interactions, we also put our focus on one outstanding
20 property among the pleiotropic actions of melatonin: its ability to promote neurogenesis
21 in the adult brain.³⁰ Neurogenesis involves the generation, maturation and integration of
22 new neurons in the neuron circuitry, which is a widespread phenomenon during
23 embryonic development. In the adult brain, neurogenesis remains vestigial and only two
24 areas retain a significant continuous neurogenic turnover, namely the subventricular
25 zone (SVZ) and the subgranular zone (SGZ) in the dentate gyrus of the hippocampus.³¹
26
27 Neurogenesis appears to modulate learning and memory integration processes³² and is
28 sensitive to physiological, pathological and pharmacological stimuli.³³ For instance,
29 ageing, neurodegenerative, and some mental diseases are associated with an exponential
30 decrease in hippocampal neurogenesis.³⁴ Therefore, the controlled pharmacological
31 stimulation of the endogenous neural stem cells from adult brain neurogenic niches
32 might counteract the age-related loss of memory and cognitive deterioration in some
33 pathological processes.³⁵
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49
50 Melatonin plasma levels decline along with age in a similar manner as the
51 neurogenic rate does.³⁶ Whether the two phenomena are related or not, remains unclear,
52 albeit melatonin positively modulates hippocampal neurogenesis by increasing both
53 precursor cell proliferation and survival, and delays the decline of neurogenesis in the
54
55
56
57
58
59
60

hippocampi of aged mice.^{37,38} This behaviour is in agreement with previous observations showing that exogenous melatonin administration, in addition to a much better retained cognitive performance, ameliorates the process of ageing by delaying the onset of deteriorated health stages in senescent mice.³⁹ Given the abovementioned properties of melatonin³⁷ and our interest in developing new melatonin-based compounds⁴⁰⁻⁴² with potential brain-repairing actions,^{43,44} we conducted a phenotypic screening *in vitro* to assess the neurogenic potential of new derivatives using rat neural stem cells.




Figure 2. Illustration showing the replacement of the acetamido moiety of melatonin carried out in this work.

RESULTS

Synthesis of New Melatonin-Based Compounds. The synthesis of all compounds here described is depicted in Scheme 1.

Synthesis of retroamides and oxazoles. *N*-Propargyl- and *N*-allyl-indolylamides **3-6** were obtained in good yields from commercial 2-(5-methoxy-1*H*-indol-3-yl)alkanoic acids that were activated with carbonyldiimidazole (CDI) and then treated with propargylamine or allylamine. Subsequently, propargyl amides **3** and **4** underwent a gold(III)-catalysed cycloisomerization,^{45,46} affording the corresponding oxazoles **7** and **8** in moderate yields.


Synthesis of 1,2,4- and 1,3,4-oxadiazoles. Intermediate ester **9** was synthesised by acid-catalysed esterification from 2-(5-methoxy-1*H*-indol-3-yl)acetic acid. Ester **10** was obtained in good yield via Michael addition of the electron-rich 5-methoxyindole with ethyl acrylate catalysed by anhydrous zirconium (IV) chloride.⁴⁷ 1,2,4-Oxadiazoles **11** and **12** were prepared directly from the corresponding esters **9** and **10** by cyclocondensation with acetamidoxime in fair yields.⁴⁸ To obtain 1,3,4-oxadiazole isomers, esters **9** and **10** were subjected to a microwave-promoted hydrazinolysis giving intermediate hydrazides **13** and **14** in quantitative yields. Then, these hydrazides underwent a condensation with the corresponding orthoester in acidic medium to afford 1,3,4-oxadiazoles **15-17**, in moderate to fair yields.

Synthesis of 1,3,4-oxadiazol-2-(thio)ones. The microwave-heating of hydrazides **13** and **14** with CDI and triethylamine (TEA) afforded the corresponding 1,3,4-oxadiazol-2-ones **18** and **19**. Similarly, the use of carbon disulfide in basic medium afforded 1,3,4-oxadiazol-2-thiones **20** and **21**.

Synthesis of 4-alkyl-1,2,4-triazol-5-(thio)ones and 2-amino-1,3,4-thiadiazole. Reaction of hydrazides **13** and **14** with methylisocyanate or ethylisothiocyanate afforded

1
2
3 the corresponding acylsemicarbazides **22** and **23**, or acylthiosemicarbazides **24** and **25**,
4
5 which underwent microwave-induced cyclocondensation in basic medium to give 4-
6
7 methyl-1,2,4-triazol-5-ones **26** and **27**, and 4-ethyl-1,2,4-triazol-5-thiones **28** and **29** in
8
9 good and very good yields, respectively. There are several methods in the literature for
10
11 the synthesis of 2-amino-1,3,4-oxadiazoles and 2-amino-1,3,4-thiadiazoles from
12
13 acylsemicarbazides and acylthiosemicarbazides. After some failed attempts with sulfuric
14
15 acid⁴⁹ and P^v-reagent,²⁶ only in the case of acylthiosemicarbazide **24** successful
16
17 cyclization to 2-amino-1,3,4-thiadiazole **30** was achieved with phosphorus oxychloride at
18
19 room temperature in fair yield.
20
21

22
23 All new melatonin-based derivatives were purified by chromatographic techniques
24
25 and structurally characterized by their analytical and spectroscopic data (HPLC, ¹H
26
27 NMR, ¹³C NMR and HRMS). Compounds **18-21**, **26-30** can exist in two possible
28
29 tautomers; for each compound, the major species (which is depicted in Scheme 1) was
30
31 determined by a combination of NMR bidimensional experiments, such as COSY
32
33 (homonuclear correlation spectroscopy), HSQC (heteronuclear single quantum
34
35 coherence) and HMBC (heteronuclear multiple bond correlation) diagrams (see
36
37 Supporting Information for further details).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 1. Reagents and conditions: (a) CDI, CH₂Cl₂, propargylamine or allylamine, rt; (b) AuCl₃, CH₂Cl₂, N₂, rt; (c) H₂SO₄ (cat.), EtOH, reflux; (d) ethylacrylate, ZrCl₄ (anh.), CH₂Cl₂, N₂, rt; (e) acetamidoxime, NaH, THF, mol. sieves, 80 °C; (f) hydrazine hydrate, 150 °C (mw), 45 min; (g) orthoester, AcOH (cat.), 125 °C (mw), 1 h; (h) compounds with X = O: CDI, TEA, THF, 100 °C (mw), 10 min; (i) compounds with X = S: CS₂, EtOH, KOH (aq.), 150 °C (mw), 10 min; (j) intermediates with X = O and R = Me: MeNCO, EtOH, rt; (k) intermediates with X = S and R = Et: EtSCN, EtOH, rt; (l) NaOH (aq.), EtOH, 100 °C (mw), 15 min; (m) POCl₃, rt.

1
2
3 **Pharmacology. Characterization at human MT₁R and MT₂R.** Binding and
4 functional activity studies of new compounds were carried out at human MT₁R or
5 MT₂R stably transfected in Chinese hamster ovary cells (CHO), using 2-
6 [¹²⁵I]iodomelatonin as radioligand and following described protocols.⁵⁰ The binding
7 affinities are gathered in Table 1. Retroamides with unsaturated side chains (**3-6**)
8 showed the highest affinities, with *K_i*s in the low nano- and sub-nanomolar range. The
9 alkenyl or alkynyl substitution does not significantly affect the potency of compounds.
10 Conversely, the length of the spacer does; ethylene spacer is preferred in both cases (**4**
11 and **6**). Compound **6** showed the highest affinities towards MTRs of all the series,
12 displaying only 3-fold lower value than melatonin at MT₂R.
13
14
15
16
17
18
19
20
21
22
23
24

25 Binding affinities of oxadiazole-bearing compounds are more favoured by the
26 presence of a methylene (**11** and **15**) than an ethylene spacer (**12**, **16**). Compared to **16**,
27 absence of the methyl substituent in the 1,3,4-oxadiazole **17** slightly increased affinity.
28 The heteroaromatic isomerism, that is 1,2,4- and 1,3,4-oxadiazole, does not seem
29 relevant in the case of methylene-oxadiazoles (**11**, **15**). Conversely, in the case of
30 ethylene-counterparts, the 1,3,4-oxadiazole (**16**) showed higher affinity than the 1,2,4-
31 oxadiazole (**12**). 1,3-Oxazoles **7** and **8** show lower binding affinities than oxadiazole
32 derivatives.
33
34
35
36
37
38
39
40
41
42

43 1,3,4-Oxadiazolones and -thiones (**18-21**), together with 1,3,4-triazol-ones and -
44 thiones (**26-29**) display a dramatic drop in binding affinity, with the remarkable
45 exception of 1,3,4-oxadiazolone **19**, which was the compound with the highest affinity
46 for both MT₁R (*K_i* = 35 nM) and MT₂R (*K_i* = 4 nM) of all synthesized azole derivatives.
47
48
49
50

51 The compound with the most marked selectivity profile [*K_i* (MT₁) / (*K_i* MT₂) >
52 500], together with rather good binding affinity at the MT₂ subtype (*K_i* = 17 nM) is the
53 2-amino-1,3,4-thiadiazole derivative **30**. Unfortunately, the synthesis of other amino-
54
55
56
57
58
59
60


1
2
3 azoles was not accomplished. Compared to **30**, the dimethylamino derivative 5-MeO-
4
5 DMT is equipotent at MT₂R ($K_i = 16$ nM), but shows much milder selectivity (around
6
7 10-fold).
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Radioligand displacement binding studies at human MT₁R and MT₂R ($K_i \pm$ SEM, nM).

Compd.	n	R	MT ₁ R	MT ₂ R	Ratio (MT ₁ /MT ₂) ^a
3	1		14 ± 4	3.8 ± 0.5	3.6
4	2		5.0 ± 0.9	1.0 ± 0.6	5
5	1		17 ± 0.7	4.9 ± 0.4	3.5
6	2		2.5 ± 0.2	0.45 ± 0.08	5.5
7	1		280 ± 20	>1000	-
8	2		>1000	498 ± 11	-
11	1		170 ± 15	44 ± 3	3.9
12	2		>1000	>1000	-
15	1		210 ± 10	16 ± 3	10
16	2		709 ± 10	190 ± 8	3.6
17	2		570 ± 10	68 ± 15	8.6
18	1		>1000	160 ± 50	-
19	2		35 ± 1	4 ± 0.5	10
20	1		>1000	535 ± 30	-
21	2		>1000	530 ± 50	-
26	1		>1000	560 ± 60	-
27	2		>1000	>1000	-
28	1		>1000	220 ± 50	-
29	2		>1000	>1000	-
30	1		>1000	17 ± 3	>500
5-MeO-DMT	2		210 ± 10	16 ± 0.5	10
Melatonin	2		0.091 ± 0.005	0.15 ± 0.07	0.6

^aRatio calculated only for compounds with $K_i < 100$ nM for either of the subtypes.

1
2
3 Only compounds showing significant affinity for either receptor ($K_i < 1000$ nM)
4
5 were functionally characterized in the [35 S]GTP γ S binding assay, and results are
6
7 summarized in Table 2. The most potent compounds were retroamides, where the spacer
8
9 length determined the intrinsic activity and potency in each pair of derivatives.
10
11 Compounds **3** and **5** with a methylene linker were partial agonists, whereas those
12
13 bearing an ethylene, **4** and **6**, were full agonists. Azole-containing compounds showed a
14
15 very similar profile, weak partial agonism at MT₂R and little or no effect at MT₁R. Only
16
17 compounds **15** and **19** displayed EC₅₀ values in the 10⁻⁸ M range at MT₂R. 5-MeO-
18
19 DMT was nearly equipotent at both receptor subtypes but showed higher efficacy at the
20
21 MT₁R than at the MT₂R.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Functional studies (GTP γ S) at MT₁R and MT₂R of selected compounds


Compd.	n	R	MT ₁ R		MT ₂ R	
			EC ₅₀ (nM)	E _{max} (%)	EC ₅₀ (nM)	E _{max} (%) ^a
3	1		289 ± 13	67 ± 8	81 ± 3	82 ± 5
4	2		38 ± 3	106 ± 9	3 ± 0.3	99 ± 9
5	1		525 ± 31	64 ± 4	132 ± 70	70 ± 8
6	2		204 ± 54	92 ± 2	11 ± 9	88 ± 4
7	1		989 ± 23	23 ± 4	nd	nd
8	2		nd	nd	503 ± 5	32 ± 1
11	1		711 ± 23	16 ± 2	295 ± 13	48 ± 2
15	1		>1000	nd	71 ± 28	24 ± 3
16	2		961 ± 16	19 ± 6	881 ± 23	32 ± 4
17	2		>1000	nd	457 ± 141	25 ± 2
18	1		nd	nd	>1000	nd
19	2		326 ± 30	26 ± 4	29 ± 3	30 ± 3
20	1		nd	nd	>1000	nd
21	2		nd	nd	1096 ± 316	32 ± 9
26	1		nd	nd	>1000	nd
28	1		nd	nd	>1000	nd
30	1		nd	nd	110 ± 25	35 ± 7
5-MeO-DMT	2		257 ± 98	62 ± 3	112 ± 110	28 ± 3
Melatonin	2		0.098 ± 0.003	100	0.069 ± 0.003	100

nd: not determined. ^aFull agonist: $E_{max} > 80\%$; Partial agonist: $20\% < E_{max} < 80\%$; Antagonist: $E_{max} < 20\%$.⁵⁰

Thermodynamic solubility studies. The thermodynamic solubility of a selection of azoles was determined in buffer at pH 7.4 (Table 3), following described protocols.^{51,52} For comparison purposes, agomelatine and melatonin were also included. Melatonin was the most soluble compound at physiologic pH. No significant differences were found between 1,2,3-oxadiazole **11** and 1,3,4-oxadiazole **15** at pH 7.4; both compounds showed a solubility similar to that of agomelatine. Additionally, for those compounds bearing acidic or basic azoles, solubility was also determined at pH 5.5 and pH 9.3 as an indirect estimation of their acid-base properties. The solubility of **19**, **21**, **27**, and **29** showed a clear dependence on the pH, peaking at basic pH values. It is especially notable in the case of **19** and **21**, demonstrating the acidic nature of these compounds. The presence of the thione group in **21**, compared to the ketone in **19**, increases the pH dependence in solubility. 2-Amino-1,3,4-thiadiazole derivative **30** also showed a mild pH difference of its solubility, higher at acidic pH, according to a weak basic nature.⁵³

Table 3. Thermodynamic solubility (μM) of selected compounds.^a

Compd.	pH 5.5	pH 7.4	pH 9.3
Melatonin	nd	6640 \pm 25	nd
Agomelatine	nd	804 \pm 24	nd
11	nd	1165 \pm 23	nd
15	nd	970 \pm 8	nd
19	1406 \pm 1	2100 \pm 20	7920 \pm 30
21	907 \pm 5	3460 \pm 200	18660 \pm 40
27	860 \pm 13	1104 \pm 17	1408 \pm 30
29	131 \pm 1	137 \pm 1	208 \pm 2
30	1718 \pm 85	1417 \pm 77	1437 \pm 78

^aResults are the mean \pm SD of three independent experiments; nd: not determined

1
2
3 ***In vitro* neural differentiation and maturation in the presence of various**
4 **melatonin analogues.** A selection of new melatonin-based compounds covering
5 different structural features, namely a propargyl derivative (**4**), an 1,3,4-oxadiazole (**16**),
6 an 1,3,4-oxadiazol-2-one (**19**) and the 2-amino-1,3,4-thiadiazole (**30**), was screened at
7 10 μM in primary cultures of neural stem cells. Melatonin and luzindole were also
8 tested for comparison purposes. Neural stem cells were obtained from the SGZ of the
9 dentate gyrus of the hippocampus of adult Wistar rats and induced to proliferate
10 forming neurospheres (NS), as previously described.^{54,55} The neurogenic potential of
11 each compound was determined by direct observation of the expression of two
12 immunostained markers, namely human β -tubulin III (TuJ1) and microtubule-associated
13 protein 2 (MAP-2) and cell nuclei were identified by staining with 4',6-diamidino-2-
14 phenylindole (DAPI). TuJ1 is expressed in neural stem cells in early stages of their
15 differentiation, whereas the expression of MAP-2 indicates a consolidated neuronal
16 stage.³¹ After incubation of SGZ-NS in the presence of the compounds (10 μM) for 7
17 days, they were allowed to differentiate for 48 h and finally, after immunostaining, the
18 expression of TuJ1 and MAP-2 was visualized by fluorescence-confocal microscopy.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Figure 3 shows the neurogenic effects of new melatonin-based compounds on
neural stem cell cultures. As expected, melatonin induced both early neurogenesis and
cell maturation.³⁰ All melatonin analogues (**4**, **16**, **19**, and **30**) promoted the expression
of TuJ1, in most cases in a larger extent than melatonin, showing also the typical
neuronal morphology. Greater differences could be observed in the expression of MAP-
2, 1,3,4-oxadiazole derivatives **16** and **19** being the most effective agents at stimulating
cell maturation, apparently even more than melatonin itself. Surprisingly, the
propargylic derivative **4**, a full agonist at both MT_1R and MT_2R and one of the most
potent melatonergic ligands in the series, did not promote MAP-2 expression.




Figure 3. Expression of TuJ1 (green) and MAP-2 (red) in cultured SGZ-derived NS in the presence of different compounds at 10 μM . DAPI (blue) was used as a nuclear marker. Scale bar, 200 μm .

1
2
3 Melatonin, compounds **16** (the most effective at stimulating the neurogenic effect *in*
4 *vitro*) and **19** (the most potent partial agonist among azoles) were further tested in the
5 presence of the non-selective antagonist luzindole (10 μ M) to evaluate the implication
6 of MT₁R and MT₂R in the expression of the neurogenic markers (Figure 4). In all three
7 cases, preincubation with luzindole blocked the expression of both TuJ1 and MAP-2
8 promoted by the tested compounds, although residual expression of both TuJ1 and
9 MAP-2 could be observed. Luzindole apparently reduced the basal expression of TuJ1
10 compared to the compound-free control.
11
12
13
14
15
16
17
18
19

20 According to the *in vitro* parallel artificial membrane permeability assay for the
21 blood-brain barrier (PAMPA-BBB), the 1,3,4-oxadiazole derivative **16** showed higher
22 passive CNS-permeability than **19** (data not shown). This non-cellular assay mimics the
23 BBB and allows a facile high-throughput evaluation of compounds in a simplified and
24 validated model.^{43,56,57} Based on the results obtained in the NS studies and its positive
25 predicted permeability in the CNS, the neurogenic profile of **16** was studied at lower
26 concentrations (1 and 0.1 μ M). Statistical analysis showed that compound **16** stimulated
27 the expression of TuJ1 and MAP-2 at all tested concentrations in SGZ-derived NS, in a
28 dose-depend manner (Figure 5).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Effect of luzindole (10 μM) on the expression of TuJ1 (green) and MAP-2 (red) promoted by melatonin, **16**, and **19** at 10 μM in SGZ-derived NS. DAPI (blue) was used as a nuclear marker. Scale bar, 200 μm .




Figure 5. (Top) Dose-response (μM) effect of compound **16** on the expression of TuJ1 (green) and MAP-2 (red) in SGZ-derived NS. DAPI (blue) was used as a nuclear marker. Scale bar, 200 μm . (Bottom) Number of TuJ1⁺ and MAP-2⁺ expressing cells in NS is shown and measured as the mean \pm SD. ** $p \leq 0.01$; *** $p \leq 0.001$.

DISCUSSION

Reversed amides have been already reported as a class of MTRs ligands, for instance, on the naphthalene series of agomelatine, but not yet on the classical 5-methoxyindole scaffold.^{19,58} Binding data showing clear preference for the ethylene spacer (**4** and **6**) are consistent with literature ones. Both compounds retain good binding affinity, possibly due to the ability to arrange their pharmacophoric groups in a way resembling that of melatonin in its bioactive conformation (Figure 6).^{6,59} This hypothesis is also supported by their full agonistic properties.





Figure 6. Superposition of melatonin (yellow carbons) in its putative bioactive conformation⁶ and **6** (green carbons).

Azole derivatives binding potency was also affected by the length of the spacer; 10-fold or higher differences were found in the case of compounds bearing the same heterocycle. The preferred spacer length depends on the nature of the azole ring. In the case of the oxazoles (**7**, **8**) the spacer seems to favour the binding to a receptor subtype, but the low affinity displayed does not allow drawing any conclusions. In the case of 1,2,4- and 1,3,4-oxadiazole matching pairs, the methylene spacer is clearly favoured (**11**

1
2
3 / **12**, **15** / **16**). These oxadiazole derivatives lack a hydrogen-donor centre compared to
4 the melatonin acetamido group. Nevertheless, the hydrogen-acceptor point can be
5 located in a nitrogen atom of the oxadiazole ring, whose relative position within the
6 heterocycle depends on the chain length (Figure 7a).



33 **Figure 7.** Compounds **15** (orange carbons), **16** (gray carbons) (panel a) and compound
34 **19** (green carbons) (panel b) superposed on melatonin (yellow carbons).
35
36

37
38
39
40
41
42 Compound **17**, the nor-isomer of **16** shows the same selectivity and potency as **15**,
43 whereas compound **16** binding is penalized in the MT₂R. This penalty is probably
44 attributable to steric clashes in the region where the amide of melatonin is
45 accommodated, worsened by the rigid coplanar arrangement of the methyl group in the
46 oxadiazole ring (Figure 7a).
47
48
49
50

51
52
53 With regard to the oxadiazole ring isomerism, the comparison between the isomer
54 pairs **11** / **15** and **12** / **16**, assuming that each pair would bind to MTRs in a similar pose,
55 demonstrates that the 1,3,4-oxadiazole ring is slightly preferred in terms of potency. The
56
57
58
59
60

1
2
3 isomerism of the oxadiazole does not seem to cause a change in the selectivity; the same
4 subtle MT₂R preference was observed for theazole compounds described by Rami et
5 al.²⁵ The carbonyl group of melatonin is putatively involved in a hydrogen bond, and
6 this moiety is necessary for binding to both receptor subtypes. On another hand, the
7 presence of the NH from the amide group is not essential in the MT₂ subtype.^{60,61} Thus,
8 the contribution of the melatonin carbonyl group to the MT₂R binding should be of
9 greater relevance. Assuming that imine-like nitrogen within the oxadiazole ring
10 substitutes for the carbonyl group of melatonin, the hydrogen bond acceptor properties
11 of the heterocycle shall be crucial for MT₂R recognition. Previous studies on both
12 oxadiazole isomers revealed that calculated hydrogen bond acceptor properties of
13 nitrogen atoms of 1,3,4-oxadiazole are greater than those of 1,2,4-oxadiazoles.²⁶ Even if
14 the contribution of this calculated difference is limited, it could explain the preference
15 of 1,3,4-oxadiazoles for MT₂R.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 In the case of acidic azoles, the affinity constants of the compounds with a
33 methylene linker (**18**, **20**, **26**, and **28**) are all within the $2 \cdot 10^{-7}$ - $6 \cdot 10^{-7}$ M range for
34 MT₂R, regardless of the nature of theazole ring or the bulk of the substituents on it.
35 Conversely, their ethylene counterparts (**19**, **21**, **27**, and **29**) showed little or no affinity
36 for either receptor subtype, with the remarkable exception of **19** that turned out to be the
37 most potent compound in the whole series of azoles. The 1,3,4-oxadiazolone ring of **19**
38 can adopt two tautomeric forms, although its NMR-characterization in DMSO showed
39 the *keto* form as the sole species. However, the acidic nature of the heterocycle, further
40 confirmed by its differential solubility at several pHs, could also imply the existence of
41 equilibrium with the conjugated base in aqueous media. Melatonin solubility in water is
42 reported to be in a range between 0.4 - 0.5 mM.^{62,63} In our experiment, the solubility of
43 melatonin in buffer solution at pH 7.4 was found to be slightly above that range (6.64
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 mM, Table 3). The solubility of **19** at pH 7.4 was lower (2.10 mM), but within the same
4
5 order of magnitude as melatonin. The bioisosteric replacement of the acetamido group
6
7 of melatonin for 1,3,4-oxadiazolone produced a lower drop (~3-fold) in solubility than
8
9 the indole-naphthalene scaffold hopping (8-fold), suggesting a comparable degree of
10
11 hydrophilicity for the 1,3,4-oxadiazolone ring and the acetamide at physiological pH. It
12
13 is not possible to determine the exact contribution of hydrophilicity, acidity, and
14
15 plausible tautomerism to the binding affinity of compound **19** since this combination of
16
17 physicochemical properties adds a great degree of complexity to the interpretation of
18
19 ligand-receptor interactions within an already elusive binding pocket. Nevertheless,
20
21 superimposition of **19** to the bioactive conformation of melatonin suggests that the
22
23 heterocyclic nitrogen closer to the ethylene spacer can mimic the carbonyl of the amide
24
25 group of melatonin (Figure 7b). Compounds **21**, **27**, and **29** could be superimposed to
26
27 the structure of melatonin in a similar manner; however, none of them displayed any
28
29 affinity for either MT₁R or MT₂R. In the case of **21**, the sulfur atom that replaces for the
30
31 carbonyl-like oxygen of **19** would reasonably affect both the acidity and the probable
32
33 tautomeric equilibrium in aqueous media. Moreover, this bioisosteric replacement
34
35 represents an additional bulk compared to the carbonyl oxygen of **19**. All three factors
36
37 could be responsible for the affinity drop of **21**. The same applies to compounds **27** and
38
39 **29**, in which not only the nature of the azole is different, but also the presence of a
40
41 substituent attached to it generates a greater bulk, more likely to be hindered by steric
42
43 clashes within the receptor binding site.
44
45
46
47
48

49
50 The binding affinity constant of **30** for the MT₂R is similar to those of methylene-
51
52 oxadiazoles **11** and **15**, with virtually no affinity for the MT₁R, showing the highest
53
54 selectivity towards the MT₂R of all compounds included in this work. This marked
55
56 selectivity could be attributed to a differential ability of either receptor subtype to
57
58
59
60

1
2
3 accommodate the slightly basic ethylamino chain of **30** within their binding pockets.
4
5 The selectivity profile of **30** encouraged us to increase the family of amino-thiadiazoles
6
7 and amino-oxadiazoles, but unfortunately the synthetic approaches failed to provide
8
9 additional analogues.
10

11
12 5-MeO-DMT shows a milder selectivity for the MT₂R than **30**. The pK_a = 8.68 of
13
14 its non-methoxylated analogue, dimethyltryptamine (DMT), suggests a predominantly
15
16 protonated state of 5-MeO-DMT at physiological pH.⁶⁴ Current knowledge of MTRs'
17
18 structure is not sufficient to devise a binding mode for basic tryptamine derivatives
19
20 based on experimental data. Displacement of 2-[¹²⁵I]iodomelatonin by 5-MeO-DMT
21
22 from hamster brain membranes was found to be 134-fold less than melatonin.²⁸ In our
23
24 case, a similar decrease in affinity was found at the human MT₂R subtype (100-fold).
25
26 Besides its long-known agonistic properties at 5-HT receptors,^{65,66} this methoxylated
27
28 tryptamine is also able to partially activate both MTRs, being 2-fold more efficient at
29
30 MT₂R. This suggests an atypical case of bioisosterism in which the protonated
31
32 dimethylamino group of 5-MeO-DMT can partially substitute for the uncharged amide
33
34 of melatonin. Considering the hypothermic effect of melatonin,⁶⁷ and the similar
35
36 affinities shown by 5-MeO-DMT for serotonin receptors (5-HT_{1A}R, K_i = 11 nM; 5-
37
38 HT_{2A}R, K_i = 92 nM)⁶⁸ and human MTRs (MT₁R, K_i = 210 nM; MT₂R, K_i = 16 nM),
39
40 these findings arise questions on whether the hypothermia observed in rats treated
41
42 consecutively with a 5-HT_{2A} antagonist and 5-MeO-DMT could be mediated not only
43
44 via 5-HTRs, but also via MTRs.²⁷
45
46
47
48

49
50 In contrast to the differences found in the binding affinities of all tested compounds
51
52 bearing a five-membered ring, their functional profile is markedly similar and appears
53
54 unaffected by the nature of the azole employed to replace the acetamido group of
55
56 melatonin. While their potencies vary depending on the compound, they all retain the
57
58
59
60

1
2
3 mild MT₂R subtype preference and are partial agonists with an E_{\max} that barely goes
4
5 above the 30% of melatonin maximum response at either receptor subtype. These
6
7 compounds, upon binding to MT₂R, presumably fit their heterocyclic substituent in the
8
9 pocket where the amide of melatonin is placed, as depicted above (exemplified for **15**
10
11 and **19** in Figure 7). Nevertheless, their relatively low binding affinity suggests that
12
13 either the accommodation of theazole ring in the region occupied by the acetamido
14
15 group of melatonin is hampered by plausible steric clashes, or that such accommodation
16
17 is secondary to some alteration in the proper arrangement of the 5-methoxyindol-3-yl-
18
19 alkyl portion. Anyway, conformational changes that lead to receptor activation would
20
21 be impeded, thus resulting in the observed weak partial agonism.
22
23

24
25 In the present study, we analysed the neurogenic effects of melatonin and some
26
27 selected synthetic analogues *in vitro* (Figure 3), and observed that the degree of
28
29 differentiation and maturation of primary neural stem cells did not correlate with their
30
31 potency at MTRs (Tables 1 and 2). Compound **4** is a full agonist, weaker than melatonin
32
33 at both MT₁R and MT₂R, yet the most potent full agonist in the series of analogues here
34
35 presented. Compound **4** induces a moderate cell differentiation, but fails to stimulate
36
37 neural maturation *in vitro*. In this regard, partial melatonergic agonists **16**, **19** and **30**
38
39 seem to perform much better at promoting neuronal development (Figure 3). Despite its
40
41 poor intrinsic activity and weak potency at MTRs, compound **16** turned out to be the
42
43 most potent compound at stimulating neurogenesis *in vitro* in a dose-dependent manner
44
45 (Figure 5), apparently in a greater extent than the reference compound melatonin.
46
47
48

49
50 In order to evaluate whether other biological pathways could be involved in the
51
52 neurogenic effect of **16**, the compound was screened at 10 μ M concentration on several
53
54 receptors reportedly related to neurogenesis, namely: glycogen synthase kinase 3 β
55
56 (GSK-3 β);⁶⁹ cannabinoid receptors 1 and 2 (CB₁, CB₂);⁷⁰ serotonin receptors subtype
57
58
59
60

1
2
3 1A, 2A, 2B, 2C (5-HT_{1A}, 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C});⁷¹ serotonin transporter (SERT);⁷²
4
5 retinoic acid receptor-alpha (RAR α); and peroxisome proliferator-activated receptor-
6
7 gamma (PPAR γ).⁷³ No significant interaction with the above-mentioned receptors was
8
9 observed.

10
11 The fact that luzindole was unable to fully block the neural differentiation *in vitro*
12 elicited by melatonin has already been observed by Ramírez-Rodríguez et al.³⁰ The
13 residual expression of TuJ1 stimulated by melatonin, **16**, and **19** in the presence of
14 luzindole (Figure 4) could be related to the interaction of these compounds with other
15 systems. Indeed, melatonin has also been reported to interact with nuclear receptors
16 from the retinoic acid superfamily, not related to MT₁R and MT₂R signalling
17 pathways.⁷⁴

18
19 Although luzindole is unable to counteract totally the effects of melatonin, **16**, or
20
21 **19**, interestingly it blocks the basal neural differentiation below its constitutive levels as
22 observed in the TuJ1 expression *in vitro* (Figure 4). This effect has already been
23 described and could be related to the nature of luzindole, a pure antagonist at MT₂R and
24 an inverse agonist at MT₁R.^{30,75} Both receptor subtypes can be found in the dentate
25 gyrus of rat hippocampus.⁷⁶ Luzindole ability to decrease melatonergic intrinsic activity
26 below its constitutive level could block, or partially block, other intracellular pathways
27 via signalling cross-talk, reducing basal neural differentiation. The magnitude of this
28 observed effect is rather low at basal levels, although it could be of relevance in the case
29 of neural differentiation elicited by compound **16**. Taking into account the low potency
30 of **16** at MTRs, a hypothetical neurogenic contribution beyond MT₁R and/or MT₂R
31 could be partially masked by a negative cross-talk.

32
33 The blockade exerted by luzindole on the neurogenic actions of melatonin, **16**, and
34
35 **19** *in vitro* suggests the involvement of MT₁R and/or MT₂R. It is surprising how weak
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 partial agonists like **16** and **19**, barely able to stimulate the MTRs activation ($\leq 30\%$
4 relative intrinsic activity in the [^{35}S]GTP γ S assay, see Table 2), are potent neurogenic
5 agents *in vitro*. To gain insights at this point, additional functional assays were carried
6 out with **16** and **19**; their intrinsic activities at MTRs were measured as impedance in
7 the case of MT₁R and as decrease of cAMP levels in the case of MT₂R.^{77,78}
8 Summarizing the results, **16** was too weak to elicit any measurable stimulation of the
9 MT₁R, whereas it reached a full agonist response at the MT₂R ($EC_{50} = 1.6 \mu\text{M}$; $E_{\text{max}} =$
10 92%). Compound **19** behaved as a full agonist at both MT₁R ($EC_{50} = 48 \text{ nM}$; $E_{\text{max}} =$
11 100%) and MT₂R ($EC_{50} = 5.5 \text{ nM}$; $E_{\text{max}} = 97\%$). A plausible hypothesis to explain these
12 observed amplification effects is functional selectivity.⁷⁹ This phenomenon is quite
13 ubiquitous in GPCRs, and MTRs are known to couple to several G-proteins, with
14 special preference for G_i proteins, that upon dissociation could differentially activate
15 parallel pathways.⁷⁴ The [^{35}S]GTP γ S assay is unable to discriminate between different
16 G-proteins but the preferential activation of certain MT_nR-G-protein populations would
17 provoke the activation of their coupled signalling pathways, and thus only their
18 mediated effects would be observed (Figure 8). These findings are insufficient to
19 establish a plausible hypothesis for the observed neurogenic effect; however, they
20 appear to suggest a distinctive activation mechanism of MTRs by azole derivatives.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 8. Schematic representation of the functional selectivity hypothesis of melatonin-azole derivatives at MTRs. (Panel a) Melatonin, the reference and native ligand, binds to MTRs coupled to G-proteins, that upon activation bind [^{35}S]GTP γ S. The amount of G-protein activated is taken arbitrarily as 100%. The size and names of the G-proteins are fictional and represent the relative population of certain activated G-protein isoforms. (Panel b) The low binding of [^{35}S]GTP γ S upon binding of melatonin-azole derivatives to MTRs could indicate the preferential activation of certain populations of $\text{MT}_n\text{-G}_n$, and subsequently, of their corresponding signalling pathways.

Conclusions

A new family of neurogenic melatonin-based drugs, covered by a PCT patent,⁸⁰ has been obtained. Maintaining the 5-methoxyindole nucleus intact we have bioisosterically replaced the acetamido group of melatonin by different reversed amides and azoles and characterized their binding affinity and functional behaviour at MT₁R and MT₂R. The retroamide replacement proved to be the best approach, yielding potent agonists at both MTR subtypes. In the case of oxadiazoles, both 1,3,4- and 1,2,4-isomers could substitute for the acetamido moiety, retaining the ability to bind to MTRs. Pharmacological and physicochemical properties of compound **19** allowed to identify the 1,3,4-oxadiazol-2-one ring as a promising starting point for further structure-activity relationship studies that could help to the understanding of the molecular recognition events occurring between MT₁R and MT₂R and the acetamido group of melatonin.

Furthermore, we have investigated the neurogenic properties of several of the abovementioned melatonin analogues *in vitro*. Even if MTRs seemingly appear implicated in mediating this effect --effectively blocked by luzindole in the case of melatonin, **16**, and **19**-- its magnitude does not correlate with compounds' potency at MT₁R and MT₂R. Such discrepancy could be possibly related to a functional selectivity phenomenon, or to interactions with additional pathways not directly related to the MT₁R or MT₂R activation, but affected by their blockade. Taking into account these observations, melatonin-azole derivatives behave as full melatonin bioisosteres in the phenotypical promotion of neurogenesis *in vitro*, well beyond their reduced ability to substitute for melatonin at MTRs. Considering its neurogenic profile, solubility and predicted CNS-permeability, we propose 2-(2-(5-methoxy-1*H*-indol-3-yl)ethyl)-5-methyl-1,3,4-oxadiazole (**16**) as a useful candidate for further development in the search for reparative agents for CNS-diseases.

EXPERIMENTAL SECTION

Chemistry. General Methods. Reagents and solvents were purchased from common commercial suppliers, mostly Sigma-Aldrich, and were used without further purification. 5-MeO-DMT was synthesized according to literature procedure.⁸¹ Analytical thin-layer chromatography (TLC) was carried out using Merck silica gel 60 F254 plates, and the compounds were visualized under UV-light ($\lambda = 254$ or 365 nm) and/or stained with phosphomolybdic acid 10% wt. in ethanol. Automatized chromatographic separation was carried out in an IsoleraOne (Biotage) equipment, using different silica Si₅₀ cartridges from Agilent Technologies. High-performance liquid chromatography was performed on a Waters analytical HPLC-MS (Alliance Waters 2690) equipped with a SunFire C₁₈ 4.6 x 50 mm column, a UV photodiode array detector ($\lambda = 214$ – 274 nm) and quadrupole mass spectrometer (Micromass ZQ). HPLC analyses were used to confirm the purity of all compounds ($\geq 95\%$) and were performed on Waters 6000 equipment, at a flow rate of 1.0 mL/min, with a UV photodiode array detector ($\lambda = 214$ – 274 nm), and using a Delta Pak C₁₈ 5 μ m, 300 Å column. The elution was performed in a gradient mixture of MeCN/water.

Melting points (uncorrected) were determined in a MP70 apparatus (Mettler Toledo). ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃, DMSO-*d*₆, or acetone-*d*₆ solutions using the following NMR spectrometers: Varian INOVA-300, Varian INOVA-400, Varian Mercury-400 or Varian Unity-500. Chemical shifts are reported in δ scale (ppm) relative to internal Me₄Si. *J* values are given in hertz, and spin multiplicities are expressed as s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet). High Resolution Mass Spectra (HRMS) were obtained by electron spray ionization in positive mode (ESI⁺) using a Hewlett-Packard MSD 1100 spectrometer.

1
2
3
4
5 **General Procedure for the Synthesis of Propargyl- or Allyl- Amides (3-6).** The
6
7 corresponding acid (1 mmol) was dissolved in dry acetonitrile (MeCN, 20 mL) and then
8
9 CDI, (1.2 mmol) and a catalytic amount of dimethylaminopyridine (DMAP, 0.01 mmol)
10
11 were added. After stirring for 2 h at 50 °C, the corresponding unsaturated amine (1
12
13 mmol) was added to the solution and the mixture was stirred for an additional 2 h period
14
15 at room temperature (rt). Then, solvent was evaporated to dryness and crude was treated
16
17 with HCl 1M (20 mL), and the resulting suspension was extracted with ethyl acetate
18
19 (EtOAc, 3 x 20 mL). The combined organic layers were washed with NaOH 2M (3 x 20
20
21 mL), dried over anhydrous MgSO₄, and evaporated to dryness in vacuo to yield the
22
23 corresponding propargyl- or allyl- amide.
24
25

26
27 ***N*-Propargyl-2-(5-methoxy-1*H*-indol-3-yl)-acetamide (3).** According to the general
28
29 procedure, from 2-(5-methoxy-1*H*-indol-3-yl)acetic acid (200 mg, 1.0 mmol) and
30
31 propargylamine (0.64 mL, 1.0 mmol), **3** (146 mg, 61%) was obtained as a white solid of
32
33 mp: 117 – 118 °C. ¹H NMR (500 MHz, DMSO) δ 10.70 (s, 1H), 8.33 (t, *J* = 5.5 Hz,
34
35 1H), 7.22 (d, *J* = 8.7 Hz, 1H), 7.13 (d, *J* = 2.4 Hz, 1H), 7.04 (d, *J* = 2.4 Hz, 1H), 6.71
36
37 (dd, *J* = 8.7, 2.5 Hz, 1H), 3.85 (dd, *J* = 5.5, 2.5 Hz, 2H), 3.75 (s, 3H), 3.47 (s, 2H), 3.08
38
39 (t, *J* = 2.5 Hz, 1H). ¹³C NMR (126 MHz, DMSO-*d*₆) δ 170.91, 153.45, 131.65, 127.93,
40
41 124.87, 112.36, 111.53, 108.73, 100.99, 81.81, 73.26, 55.79, 32.93, 28.39. HRMS
42
43 (ESI⁺): *m/z* calcd for C₁₄H₁₄N₂O₂ (M)⁺ 242.1055, found 242.1063. HPLC purity 100%
44
45 (230 to 400 nm).
46
47

48
49 ***N*-Propargyl-3-(5-methoxy-1*H*-indol-3-yl)-propanamide (4).** Following the general
50
51 procedure, from 3-(5-methoxy-1*H*-indol-3-yl)propanoic acid (219 mg, 1.0 mmol) and
52
53 propargylamine (0.71 mL, 1.1 mmol), **4** (167 mg, 65%) was obtained as a white solid of
54
55 mp: 118 – 119 °C. ¹H NMR (300 MHz, acetone-*d*₆) δ 7.25 (d, *J* = 8.8 Hz, 1H), 7.12 –
56
57
58
59
60

1
2
3 7.04 (m, 2H), 6.74 (dd, $J = 8.8, 2.5$ Hz, 1H), 3.98 (d, $J = 2.6$ Hz, 2H), 3.80 (s, 3H), 3.02
4 (t, $J = 7.7$ Hz, 2H), 2.61 (t, $J = 2.6$ Hz, 1H), 2.56 (m, 2H). ^{13}C NMR (75 MHz, acetone)
5
6 δ 173.16, 155.26, 133.31, 129.32, 124.06, 115.76, 113.29, 112.93, 101.79, 82.19, 72.44,
7
8 56.54, 37.93, 29.38, 22.54. HRMS (ESI⁺): m/z calcd for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_2$ (M)⁺ 256.1212,
9
10 found 256.1202. HPLC purity 97% (230 to 400 nm).

11
12
13
14 ***N*-Allyl-2-(5-methoxy-1*H*-indol-3-yl)acetamide (5)**. According to the general
15
16 procedure, from 2-(5-methoxy-1*H*-indol-3-yl)acetic acid (168 mg, 0.84 mmol) and
17
18 allylamine (92 μL , 1.26 mmol), **5** (178 mg, 86%) was obtained as a yellow oil that
19
20 crystallised upon standing. Mp: 92 – 93 °C. ^1H NMR (300 MHz, DMSO) δ 10.69 (s,
21
22 1H), 8.05 – 7.97 (m, 1H), 7.21 (d, $J = 8.7$ Hz, 1H), 7.13 (d, $J = 2.2$ Hz, 1H), 7.06 (d, $J =$
23
24 2.4 Hz, 1H), 6.70 (dd, $J = 8.7, 2.4$ Hz, 1H), 5.77 (ddt, $J = 17.1, 10.3, 5.2$ Hz, 1H), 5.08
25
26 (dd, $J = 17.1, 1.8$ Hz, 1H), 5.00 (dd, $J = 10.3, 1.8$ Hz, 1H), 3.73 (s, 3H), 3.68 (m, 2H),
27
28 3.48 (s, 2H). ^{13}C NMR (75 MHz, DMSO) δ 170.51, 152.96, 135.49, 131.21, 127.49,
29
30 124.42, 114.85, 111.90, 111.04, 108.61, 100.53, 55.30, 40.90, 32.70. HRMS (ESI⁺): m/z
31
32 calcd for $\text{C}_{14}\text{H}_{16}\text{N}_2\text{O}_2$ (M)⁺ 244.1212, found 244.1202. HPLC purity 100% (230 to 400
33
34 nm).

35
36
37
38 ***N*-Allyl-3-(5-methoxy-1*H*-indol-3-yl)propanamide (6)**. Following the general
39
40 procedure, from 3-(5-methoxy-1*H*-indol-3-yl)propanoic acid (80 mg, 0.36 mmol) and
41
42 allylamine (40 μL , 0.54 mmol), **6** (81 mg, 87%) was obtained as a brownish solid of
43
44 mp: 173 – 174 °C. ^1H NMR (300 MHz, DMSO) δ 10.58 (s, 1H), 7.99 (t, $J = 5.1$ Hz,
45
46 1H), 7.21 (d, $J = 8.7$ Hz, 1H), 7.05 (d, $J = 2.1$ Hz, 1H), 7.00 (d, $J = 2.4$ Hz, 1H), 6.71
47
48 (dd, $J = 8.7, 2.4$ Hz, 1H), 5.77 (ddt, $J = 17.2, 10.4, 5.2$ Hz, 1H), 5.08 (dd, $J = 17.3, 1.8$
49
50 Hz, 1H), 5.02 (dd, $J = 10.3, 1.7$ Hz, 1H), 3.76 (s, 3H), 3.70 (t, $J = 5.5$ Hz, 2H), 2.89 (t, J
51
52 = 7.5 Hz, 2H), 2.45 (t, $J = 7.5$ Hz, 2H). ^{13}C NMR (75 MHz, DMSO) δ 172.08, 153.25,
53
54 135.88, 131.73, 127.67, 123.14, 115.31, 113.98, 112.25, 111.34, 100.62, 55.72, 41.18,
55
56
57
58
59
60

1
2
3 36.48, 21.44. HRMS (ESI⁺): *m/z* calcd for C₁₅H₁₈N₂O₂ (M)⁺ 258.1368, found 258.1370.
4
5 HPLC purity 100% (230 to 400 nm).
6

7 **Synthesis of Oxazoles. 2-((5-Methoxy-1*H*-indol-3-yl)methyl)-5-methyloxazole (7).**
8

9 To a solution of **3** (100 mg, 0.41 mmol) in 10 mL of dry dichloromethane, gold(III)
10 chloride (12 mg, 0.041 mmol) was added and the resulting mixture was stirred at rt for
11 18 h under inert atmosphere. After this time, TEA (0.5 mL) was added and the reaction
12 mixture was filtered over a short plug of silica gel eluting with EtOAc. Solvent was
13 evaporated to dryness and the resulting oil was chromatographed on silica gel (gradient
14 hexane: EtOAc) to afford **7** (18 mg, 18%) as a coloured solid of mp: 106 – 108 °C. ¹H
15 NMR (300 MHz, CDCl₃) δ 8.35 (s, 1H), 7.25 (d, *J* = 8.8 Hz, 1H), 7.17 – 7.05 (m, 2H),
16 6.85 (dd, *J* = 8.8, 2.5 Hz, 1H), 6.66 (s, 1H), 4.21 (s, 2H), 3.85 (s, 3H), 2.26 (s, 3H). ¹³C
17 NMR (101 MHz, CDCl₃) δ 161.52, 154.30, 144.90, 131.45, 127.62, 123.57, 122.55,
18 112.74, 112.03, 110.12, 100.77, 56.02, 25.07, 11.08. HRMS (ESI⁺): *m/z* calcd for
19 C₁₄H₁₄N₂O₂ (M)⁺ 242.1055, found 242.1055. HPLC purity 100% (230 to 400 nm).
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **2-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-5-methyloxazole (8).** Starting from **4** (30 mg,
35 0.11 mmol), this derivative was synthesized according to the procedure described for **7**,
36 obtaining **8** (11 mg, 38%) as a light brown solid of mp: 100 – 105 °C. ¹H NMR (300
37 MHz, CDCl₃) δ 7.94 (s, 1H), 7.25 (d, *J* = 8.8 Hz, 1H), 7.03 (d, *J* = 2.3 Hz, 1H), 7.00 (s,
38 1H), 6.86 (dd, *J* = 8.8, 2.3 Hz, 1H), 6.64 (s, 1H), 3.87 (s, 3H), 3.23-3.18 (m, 1H), 3.13-
39 3.08 (m, 1H), 2.28 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.51, 154.08, 148.39,
40 131.48, 127.72, 122.53, 122.31, 114.90, 112.45, 111.98, 100.54, 56.06, 29.03, 22.97,
41 11.01. HRMS (ESI⁺): *m/z* calcd for C₁₅H₁₆N₂O₂ (M)⁺ 256.1212, found 256.1209. HPLC
42 purity 95% (230 to 400 nm).
43
44
45
46
47
48
49
50
51
52
53

54 **Synthesis of Esters. Ethyl 2-(5-methoxy-1*H*-indol-3-yl)acetate (9).**⁸² To a solution of
55 2-(5-methoxy-1*H*-indol-3-yl)acetic acid (3.5 g, 17.07 mmol) in 50 mL of EtOH 25
56
57
58
59
60

1
2
3 drops of concentrated sulfuric acid were added. The mixture was heated under reflux for
4
5 2 h, cooled to rt, neutralized with a solution of NaOH 2M, and evaporated to dryness in
6
7 vacuo. The residue was treated with water (40 mL) and extracted with EtOAc (3 x 40
8
9 mL). Removal of the organic solvent under reduced pressure gave **9** (3.42 mg, 86%) as
10
11 a light yellow solid. ¹H NMR (300 MHz, DMSO) δ 10.77 (s, 1H), 7.23 (d, *J* = 8.7 Hz,
12
13 1H), 7.19 (d, *J* = 2.3 Hz, 1H), 6.98 (d, *J* = 2.4 Hz, 1H), 6.72 (dd, *J* = 8.7, 2.4 Hz, 1H),
14
15 4.07 (q, *J* = 7.1 Hz, 2H), 3.74 (s, 3H), 3.68 (s, 2H), 1.18 (t, *J* = 7.1 Hz, 3H). ¹³C NMR
16
17 (75 MHz, DMSO) δ 171.52, 153.06, 131.19, 127.38, 124.61, 112.04, 111.19, 106.75,
18
19 100.27, 59.98, 55.26, 30.89, 14.14. HPLC-MS (230 to 400 nm) 100% (*m/z*) [MH⁺]
20
21 234.44.
22
23

24
25 **Ethyl 3-(5-methoxy-1*H*-indol-3-yl)propanoate (10).**⁸³ To a solution of 5-methoxy-
26
27 1*H*-indole (5.0 g, 34 mmol) and ethyl acrylate (21.7 mL, 0.2 mol) in DCM (40 mL),
28
29 anhydrous ZrCl₄ (1.0 g, 4.29 mmol) was added and the mixture was kept stirring at rt
30
31 for 18 h. Then, the catalyst was filtered off and the solvent and excess of ethyl acrylate
32
33 were removed under vacuum and collected in a cold trap. The resulting crude was
34
35 chromatographed on silica gel (gradient DCM: MeOH) to afford **10** (6.1 g, 71%) as a
36
37 white pearly solid. ¹H NMR (300 MHz, CDCl₃) δ 7.88 (s, 1H), 7.24 (d, *J* = 8.8 Hz, 1H),
38
39 7.04 (d, *J* = 2.3 Hz, 1H), 6.99 (s, 1H), 6.86 (dd, *J* = 8.8, 2.3 Hz, 1H), 4.15 (q, *J* = 7.1 Hz,
40
41 2H), 3.87 (s, 3H), 3.07 (t, *J* = 7.6 Hz, 2H), 2.71 (t, *J* = 7.6 Hz, 2H), 1.25 (t, *J* = 7.1 Hz,
42
43 3H). ¹³C NMR (75 MHz, CDCl₃) δ 173.40, 153.93, 131.38, 127.55, 122.12, 114.77,
44
45 112.22, 111.77, 100.56, 60.32, 55.92, 34.81, 20.60, 14.19. HPLC-MS (230 to 400 nm)
46
47 100% (*m/z*) [MH⁺] 248.06.
48
49
50

51
52 **Synthesis of 1,2,4-Oxadiazoles. 5-((5-Methoxy-1*H*-indol-3-yl)methyl)-3-methyl-**
53
54 **1,2,4-oxadiazole (11).** Acetamidoxime (95 mg, 1.3 mmol), 1.5 g of molecular sieves
55
56 (3Å), and sodium hydride (61 mg, 2.5 mmol) were suspended in anhydrous THF (4 mL)
57
58
59
60

1
2
3 and stirred at 50 °C. After stirring for 2 h, **9** (150 mg, 0.64 mmol) dissolved in THF (2
4 mL) was slowly added to the mixture that was kept with gentle stirring for additional 18
5 h. Then, the mixture was filtered and the solids washed with EtOAc (10 mL). The
6 filtrate was evaporated under vacuum and the crude was chromatographed on silica gel
7 (gradient DCM: MeOH) to afford **11** (87 mg, 56%) as a brownish solid of mp: 100 –
8 102 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.07 (s, 1H), 7.28-7.25 (m, 1H), 7.21 (s, 1H),
9 7.05 (d, *J* = 2.4 Hz, 1H), 6.88 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.32 (s, 2H), 3.87 (s, 3H), 2.38
10 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 178.54, 167.55, 154.68, 131.54, 127.45, 124.04,
11 113.20, 112.36, 108.07, 100.63, 56.19, 23.56, 11.91. HRMS (ESI⁺): *m/z* calcd for
12 C₁₃H₁₃N₃O₂ (M)⁺ 243.1017, found 243.1008. HPLC purity 100% (230 to 400 nm).

13
14
15
16
17
18
19
20
21
22
23
24
25 **5-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-3-methyl-1,2,4-oxadiazole (12)**. Starting from
26 **10** (173 mg, 0.7 mmol), the compound was synthesized according to the procedure
27 described for **11**, obtaining **12** (80 mg, 45%) as an off-white solid of mp: 75 – 76 °C. ¹H
28 NMR (400 MHz, DMSO) δ 10.66 (s, 1H), 7.21 (d, *J* = 8.7 Hz, 1H), 7.09 (d, *J* = 2.4 Hz,
29 1H), 6.99 (d, *J* = 2.4 Hz, 1H), 6.71 (dd, *J* = 8.7, 2.4 Hz, 1H), 3.76 (s, 3H), 3.23 (t, *J* =
30 7.3 Hz, 2H), 3.12 (t, *J* = 7.3 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (100 MHz, DMSO) δ
31 180.04, 167.35, 153.71, 131.95, 127.73, 123.90, 112.82, 112.73, 111.95, 100.54, 55.99,
32 27.40, 22.58, 11.80. HRMS (ESI⁺): *m/z* calcd for C₁₄H₁₅N₃O₂ (M)⁺ 257.1164, found
33 257.1172. HPLC purity 100% (230 to 400 nm).

34
35
36
37
38
39
40
41
42
43
44
45 **Synthesis of hydrazides. 2-(5-Methoxy-1*H*-indol-3-yl)acetohydrazide (13)**.⁸⁴ A
46 mixture of **9** (1.53 g, 6.5 mmol) and excess of hydrazine hydrate (5 mL) in EtOH (6
47 mL) was heated to 155 °C for 45 min under microwave irradiation. After removing the
48 solvent, the milky crude was resuspended in water (70 mL) and extracted with EtOAc
49 (6 x 50 mL). The organic extracts were dried over anhydrous magnesium sulfate and
50 solvent removed to give **13** (1.40 g, 98%) as a white solid. ¹H NMR (300 MHz, DMSO)
51
52
53
54
55
56
57
58
59
60

1
2
3 δ 10.76 (s, 1H), 9.09 (s, 1H), 7.20 (d, $J = 8.7$ Hz, 1H), 7.12 (d, $J = 2.3$ Hz, 1H), 7.06 (d,
4 $J = 2.4$ Hz, 1H), 6.69 (dd, $J = 8.7, 2.4$ Hz, 1H), 4.17 (s, 2H), 3.74 (s, 3H), 3.39 (s, 2H).
5
6 ^{13}C NMR (75 MHz, DMSO) δ 170.13, 152.94, 131.16, 127.48, 124.31, 111.83, 110.92,
7
8 108.41, 100.71, 55.35, 30.74. HPLC-MS (230 to 400 nm) 100% (m/z) [MH^+] 220.11.
9

10
11 **3-(5-Methoxy-1*H*-indol-3-yl)propanehydrazide (14)**. Starting from **10** (3.0 g, 12.1
12 mmol), this compound was synthesized according to the procedure described for **13**,
13
14 obtaining **14** (2.8 g, 100%) as an off-white solid. ^1H NMR (300 MHz, DMSO) δ 10.59
15
16 (s, 1H), 9.00 (s, 1H), 7.20 (d, $J = 8.7$ Hz, 1H), 7.04 (d, $J = 2.2$ Hz, 1H), 6.98 (d, $J = 2.4$
17
18 Hz, 1H), 6.70 (dd, $J = 8.7, 2.4$ Hz, 1H), 4.18 (s, 2H), 3.76 (s, 3H), 2.87 (t, $J = 8.0$ Hz,
19
20 2H), 2.37 (t, $J = 8.0$ Hz, 2H). HPLC-MS (230 to 400 nm) 96% (m/z) [MH^+] 234.08.
21
22

23
24 **General procedure for the Synthesis of 1,3,4-Oxadiazoles**. The corresponding
25
26 hydrazide (0.5 mmol) was suspended in an excess of an orthoester (1 mL) and a
27
28 catalytic amount of acetic acid (1 drop) was added. The mixture was heated in a
29
30 microwave system for 1 h at 125 °C. Then, the excess of the orthoester was evaporated
31
32 to dryness and the crude chromatographed on silica gel (gradient DCM:MeOH),
33
34 obtaining the corresponding 1,3,4-oxadiazole.
35
36

37
38 **2-((5-Methoxy-1*H*-indol-3-yl)methyl)-5-methyl-1,3,4-oxadiazole (15)**. According to
39
40 the above general procedure, from **13** (100 mg, 0.45 mmol), triethyl orthoacetate (1 mL)
41
42 and a catalytic amount of acetic acid, **15** (71 mg, 64%) was obtained as a brownish solid
43
44 of mp: 139 – 140 °C. ^1H NMR (300 MHz, CDCl_3) δ 8.33 (s, 1H), 7.25 (d, $J = 8.8$ Hz,
45
46 1H), 7.14 (s, 1H), 7.06 (d, $J = 2.3$ Hz, 1H), 6.86 (dd, $J = 8.8, 2.3$ Hz, 1H), 4.27 (s, 2H),
47
48 3.84 (s, 3H), 2.44 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 165.95, 163.93, 154.25,
49
50 131.26, 127.15, 123.78, 112.75, 112.09, 107.86, 100.24, 55.85, 22.09, 10.94. HRMS
51
52 (ESI^+): m/z calcd for $\text{C}_{13}\text{H}_{13}\text{N}_3\text{O}_2$ (M) $^+$ 243.1008, found 243.1017. HPLC purity 100%
53
54 (230 to 400 nm).
55
56
57
58
59
60

1
2
3 **2-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-5-methyl-1,3,4-oxadiazole (16)**. Following the
4
5 general procedure, from **14** (405 mg, 1.74 mmol), triethyl orthoacetate (3.5 mL) and a
6
7 catalytic amount of acetic acid, derivative **16** (257 mg, 57%) was obtained as a
8
9 brownish solid of mp: 156 – 157 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.03 (s, 1H), 7.91
10
11 (s, 1H), 7.25 (d, *J* = 8.8 Hz, 1H), 7.01 (s, 1H), 6.99 (d, *J* = 2.4 Hz, 1H), 6.87 (dd, *J* =
12
13 8.8, 2.4 Hz, 1H), 3.87 (s, 3H), 3.24 – 3.20 (m, 4H), 2.47 (s, 3H). ¹³C NMR (75 MHz,
14
15 CDCl₃) δ 166.79, 163.64, 154.05, 131.37, 127.39, 122.40, 113.78, 112.34, 111.95,
16
17 100.28, 55.93, 26.17, 22.34, 10.90. HRMS (ESI⁺): *m/z* calcd for C₁₄H₁₅N₃O₂ (M)⁺
18
19 257.1164, found 257.1158. HPLC purity 100% (230 to 400 nm).
20
21

22
23 **2-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-1,3,4-oxadiazole (17)**. According to the above
24
25 general procedure, from **14** (120 mg, 0.5 mmol), trimethyl orthoformate (1 mL) and a
26
27 catalytic amount of acetic acid, compound **17** (41 mg, 34%) was obtained as an off-
28
29 white solid of mp: 148 – 149 °C. ¹H NMR (300 MHz, DMSO) δ 9.73 (s, 1H), 8.40 (s,
30
31 1H), 7.18 (d, *J* = 8.8 Hz, 1H), 6.92 (d, *J* = 2.5 Hz, 1H), 6.87 (d, *J* = 2.5 Hz, 1H), 6.71
32
33 (dd, *J* = 8.7, 2.5 Hz, 1H), 3.76 (s, 3H), 3.23 – 3.14 (m, 4H). ¹³C NMR (75 MHz,
34
35 DMSO) δ 165.54, 152.51, 152.08, 130.55, 126.06, 121.78, 111.40, 111.15, 110.63,
36
37 98.79, 54.71, 24.99, 21.28. HRMS (ESI⁺): *m/z* calcd for C₁₃H₁₃N₃O₂ (M)⁺ 243.1008,
38
39 found 243.1014. HPLC purity 98% (230 to 400 nm).
40
41

42
43 **Synthesis of 1,3,4-oxadiazol-2-(thio)ones. 5-((5-Methoxy-1*H*-indol-3-yl)methyl)-**
44
45 **1,3,4-oxadiazol-2(3*H*)-one (18)**. A mixture of **13** (86 mg, 0.4 mmol), CDI (76 mg, 0.47
46
47 mmol), TEA (0.11 mL, 0.8 mmol) dissolved in THF was heated to 100 °C for 15 min.
48
49 Solvent was evaporated and the residue was treated with a small amount of water (2
50
51 mL), basified to pH 12-13 with NaOH (conc.) and filtered. The filtrate was collected
52
53 and acidified with HCl (conc.) and thus, the compound precipitated. The precipitate was
54
55 filtered off to afford **18** (72 mg, 73%) as a pearly white solid of mp 140 – 141 °C. ¹H
56
57
58
59
60

1
2
3 NMR (300 MHz, DMSO) δ 12.08 (s, 1H), 10.89 (s, 1H), 7.26 (d, J = 8.8 Hz, 1H), 7.24
4 (s, 1H), 7.00 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 8.8, 2.4 Hz, 1H), 3.97 (s, 2H), 3.73 (s,
5 3H). ^{13}C NMR (75 MHz, DMSO) δ 156.46, 155.07, 153.18, 131.24, 127.03, 124.78,
6 112.22, 111.27, 105.87, 100.11, 55.30, 22.54. HRMS (ESI⁺): m/z calcd for C₁₂H₁₁N₃O₃
7 (M)⁺ 245.0800, found 246.0802. HPLC purity 100% (230 to 400 nm).
8
9

10
11
12
13
14 **5-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-1,3,4-oxadiazol-2(3H)-one (19)**. Starting from
15 14 (146 mg, 0.62 mmol) and following the procedure described for 18, oxadiazolone 19
16 (138 mg, 86%) was obtained as an off-white solid of mp 140 – 144 °C. ^1H NMR (400
17 MHz, DMSO) δ 12.00 (s, 1H), 10.66 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.09 (d, J = 2.3
18 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.69 (dd, J = 8.7, 2.4 Hz, 1H), 3.74 (s, 3H), 2.97 (t, J
19 = 7.6 Hz, 2H), 2.85 (t, J = 7.6 Hz, 2H). ^{13}C NMR (101 MHz, DMSO) δ 157.65, 155.77,
20 153.70, 131.92, 127.77, 124.00, 112.76, 112.72, 111.93, 100.36, 55.92, 27.55, 21.54.
21 HRMS (ESI⁺): m/z calcd for C₁₃H₁₃N₃O₃ (M)⁺ 259.0957, found 259.0966. HPLC purity
22 100% (230 to 400 nm).
23
24
25
26
27
28
29
30
31
32

33
34 **5-((5-Methoxy-1H-indol-3-yl)methyl)-1,3,4-oxadiazole-2(3H)-thione (20)**. A mixture
35 of **13** (83 mg, 0.37 mmol), KOH (70 mg, 1.24 mmol) and an excess of carbon disulfide
36 (1.35 mL, 38 mmol) in EtOH was heated to 155 °C for 10 min under microwave
37 irradiation. Solvent and carbon disulfide excess were evaporated under reduced pressure
38 and the residue treated with water. The solution was acidified with conc. HCl and **20**
39 (91 mg, 95%) precipitated as a yellow solid of mp 171 – 173 °C that was filtered off. ^1H
40 NMR (300 MHz, DMSO) δ 14.35 (s, 1H), 10.94 (s, 1H), 7.30 (s, 1H), 7.28 (d, J = 8.8
41 Hz, 1H), 7.02 (d, J = 2.3 Hz, 1H), 6.76 (dd, J = 8.8, 2.4 Hz, 1H), 4.19 (s, 2H), 3.75 (s,
42 3H). ^{13}C NMR (75 MHz, DMSO) δ 177.73, 163.44, 153.25, 131.23, 126.94, 125.01,
43 112.28, 111.38, 105.39, 100.08, 55.31, 21.74. HRMS (ESI⁺): m/z calcd for
44 C₁₂H₁₁N₃O₂S (M)⁺ 261.0572, found 261.0577. HPLC purity 100% (230 to 400 nm).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **5-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-1,3,4-oxadiazole-2(3*H*)-thione (21)**. Starting
4
5 from **14** (116 mg, 0.5 mmol) and following the procedure described for **20**, derivative
6
7 **21** (56 mg, 41%) was obtained as an off-white solid of mp 99 – 101 °C. ¹H NMR (400
8
9 MHz, DMSO) δ 14.29 (s, 1H), 10.70 (s, 1H), 7.21 (d, *J* = 8.7 Hz, 1H), 7.11 (d, *J* = 2.4
10
11 Hz, 1H), 6.97 (d, *J* = 2.4 Hz, 1H), 6.70 (dd, *J* = 8.7, 2.4 Hz, 1H), 3.76 (s, 3H), 3.10 –
12
13 2.97 (m, 4H). ¹³C NMR (101 MHz, DMSO) δ 177.69, 164.05, 153.08, 131.25, 127.06,
14
15 123.38, 112.12, 111.84, 111.37, 99.70, 55.31, 26.14, 21.05. HRMS (ESI⁺): *m/z* calcd for
16
17 C₁₃H₁₃N₃O₂S (M)⁺ 275.0728, found 275.0726. HPLC purity 95% (230 to 400 nm).
18
19
20
21
22

23 **General Method for the Synthesis of Acyl(thio)semicarbazides**. To a solution of a
24
25 hydrazide (1 mmol) in EtOH (10 mL) the corresponding isocyanate or isothiocyanate (1
26
27 mmol) was added. The mixture was kept stirring at rt until the reaction was finished,
28
29 typically 1 h in the case of methylisocyanate. Longer times were needed in the case of
30
31 ethylisothiocyanate. Then, solvent was removed and the resulting solid used as such for
32
33 the next step without further purification.
34
35

36 **1-(2-(5-Methoxy-1*H*-indol-3-yl)acetyl)-4-methylsemicarbazide (22)**. According to
37
38 the general method, from **13** (73 mg, 0.33 mmol) and methylisocyanate (21 μL, 0.33
39
40 mmol) and after 1 h stirring at rt, intermediate **22** (91 mg, 99%) was obtained as a white
41
42 solid. HPLC-MS (230 to 400 nm) 97% (*m/z*) [MH⁺] 277.37.
43
44

45 **1-(3-(5-Methoxy-1*H*-indol-3-yl)propanoyl)-4-methylsemicarbazide (23)**. Following
46
47 the general method, the 1h-stirring of **14** (230 mg, 0.98 mmol) and methylisocyanate
48
49 (68 μL, 1 mmol) yielded intermediate **23** (290 mg, 100%) as a white solid. HPLC-MS
50
51 (230 to 400 nm) 98% (*m/z*) [MH⁺] 291.40.
52
53

54 **1-(2-(5-Methoxy-1*H*-indol-3-yl)acetyl)-4-ethylthiosemicarbazide (24)**. According to
55
56 the general method, the 18h-stirring at rt of **13** (116 mg, 0.5 mmol) and
57
58
59
60

1
2
3 ethylisothiocyanate (44 μ L, 0.5 mmol) gave intermediate **24** (150 mg, 94%) as a white
4
5 solid. HPLC-MS (230 to 400 nm) 99% (m/z) [MH⁺] 307.37.
6

7 **1-(3-(5-Methoxy-1*H*-indol-3-yl)propanoyl)-4-ethylthiosemicarbazide (25).**

8
9 According to the general method, from **14** (506 mg, 2.17 mmol) and ethylisothiocyanate
10
11 (190 μ L, 2.17 mmol), using 18h of reaction at rt, intermediate **25** (707 mg, 100%) was
12
13 obtained as a white solid. HPLC-MS (230 to 400 nm) 90% (m/z) [MH⁺] 321.26.
14
15
16
17

18 **General Method for the Synthesis of 1,2,4-Triazol-5-(thi)ones.** The corresponding
19
20 acylsemicarbazide or acylthiosemicarbazide (1 mmol) was dissolved in EtOH (10 mL)
21
22 and NaOH 2M (7 mL) was added. The mixture was heated under microwave irradiation
23
24 at 100 °C for 15 min. The solvent was evaporated and the crude dissolved in water. The
25
26 mixture was acidified to pH 2 with conc. HCl and the corresponding triazole
27
28 precipitated off the solution, being collected by filtration. When necessary, the
29
30 precipitate was chromatographed in silica gel (gradient DCM:MeOH) for further
31
32 purification.
33
34
35

36 **3-((5-Methoxy-1*H*-indol-3-yl)methyl)-4-methyl-1*H*-1,2,4-triazol-5(4*H*)-one (26).**

37
38 According to the above general method, from **22** (82 mg, 0.3 mmol), triazole **26** (58 mg,
39
40 75%) was obtained as a light orange pearly solid of mp 218 – 219 °C. ¹H NMR (300
41
42 MHz, DMSO) δ 11.41 (s, 1H), 10.82 (s, 1H), 7.25 (d, *J* = 8.8 Hz, 1H), 7.20 (d, *J* = 2.3
43
44 Hz, 1H), 7.01 (d, *J* = 2.4 Hz, 1H), 6.74 (dd, *J* = 8.8, 2.4 Hz, 1H), 3.95 (s, 2H), 3.72 (s,
45
46 3H), 2.98 (s, 3H). ¹³C NMR (75 MHz, DMSO) δ 155.65, 153.43, 147.20, 131.77,
47
48 127.50, 124.77, 112.51, 111.55, 107.40, 100.68, 55.65, 26.88, 22.86. HRMS (ESI⁺): *m/z*
49
50 calcd for C₁₃H₁₄N₄O₂ (M)⁺ 258.1117, found 258.1113. HPLC purity 100% (230 to 400
51
52 nm).
53
54
55
56
57
58
59
60

3-(2-(5-Methoxy-1*H*-indol-3-yl)ethyl)-4-methyl-1*H*-1,2,4-triazol-5(4*H*)-one (27).

Following the general method, from **23** (290 mg, 1 mmol) and after a chromatographic purification on silica gel, **27** (110 mg, 41%) was obtained as a white powder of mp 201 – 202 °C. ¹H NMR (500 MHz, DMSO) δ 11.38 (s, 1H), 10.67 (s, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 7.12 (d, *J* = 2.4 Hz, 1H), 6.94 (d, *J* = 2.4 Hz, 1H), 6.70 (dd, *J* = 8.8, 2.4 Hz, 1H), 3.75 (s, 3H), 3.01 (s, 3H), 2.98 (t, *J* = 8.0 Hz, 2H), 2.82 (t, *J* = 8.0 Hz, 2H). ¹³C NMR (126 MHz, DMSO) δ 155.65, 153.39, 148.13, 131.70, 127.66, 123.70, 113.24, 112.45, 111.60, 100.26, 55.68, 26.75, 26.74, 21.74. HRMS (ESI⁺): Calcd. for C₁₄H₁₆N₄O₂ (M)⁺ 272.1283, found *m/z* 272.1273. HPLC purity 100% (230 to 400 nm).

4-Ethyl-3-((5-methoxy-1*H*-indol-3-yl)methyl)-1*H*-1,2,4-triazol-5(4*H*)-thione (28).

According to the general method, from **24** (40 mg, 0.13 mmol), triazole **28** (30 mg, 80%) was obtained as a shiny brownish solid of mp: 200 - 203 °C. ¹H NMR (300 MHz, DMSO) δ 13.51 (s, 1H), 10.87 (s, 1H), 7.27 (d, *J* = 2.5 Hz, 1H), 7.25 (d, *J* = 8.8 Hz, 1H), 6.98 (d, *J* = 2.4 Hz, 1H), 6.74 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.16 (s, 2H), 3.90 (q, *J* = 7.1 Hz, 2H), 3.72 (s, 3H), 0.93 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (75 MHz, DMSO) δ 166.63, 153.49, 151.61, 131.74, 127.43, 125.08, 112.60, 111.58, 107.29, 100.65, 55.65, 38.62, 22.22, 13.23. HRMS (ESI⁺): *m/z* calcd for C₁₄H₁₆N₄OS (M)⁺ 288.1045, found 288.1036. HPLC purity 100% (230 to 400 nm).

4-Ethyl-3-(2-(5-methoxy-1*H*-indol-3-yl)ethyl)-1*H*-1,2,4-triazol-5(4*H*)-thione (29).

Following the general method, from **25** (200 mg, 0.62 mmol), and after chromatographic purification on silica gel, **29** (140 mg, 84%) was obtained as a white powder of mp 214 – 217 °C. ¹H NMR (500 MHz, DMSO) δ 13.52 (s, 1H), 10.68 (s, 1H), 7.22 (d, *J* = 8.7 Hz, 1H), 7.14 (d, *J* = 2.4 Hz, 1H), 6.96 (d, *J* = 2.4 Hz, 1H), 6.70 (dd, *J* = 8.7, 2.4 Hz, 1H), 3.91 (q, *J* = 7.2 Hz, 2H), 3.75 (s, 3H), 3.06 – 3.02 (m, 2H), 3.02 – 2.97 (m, 2H), 1.14 (t, *J* = 7.2 Hz, 3H). ¹³C NMR (126 MHz, DMSO) δ 166.26,

1
2
3 153.42, 152.45, 131.69, 127.60, 123.77, 113.04, 112.48, 111.66, 100.24, 55.69, 38.40,
4
5 26.15, 22.05, 13.77. HRMS (ESI⁺): Calcd for C₁₅H₁₈N₄OS (M)⁺ 302.1201, found *m/z*
6
7 302.1207. HPLC-MS (230 to 400 nm) 98% (*m/z*) (M⁺) 303.28.
8

9
10 ***N*-Ethyl-5-((5-methoxy-1*H*-indol-3-yl)methyl)-1,3,4-thiadiazol-2-amine (30).**
11
12 POCl₃ (1 mL) was added over intermediate **24** (92 mg, 0.3 mmol) and the mixture kept
13
14 stirring at rt for 18 h. After this time, water (10 mL) was carefully added to the mixture
15
16 and then basified at 0 °C to pH 9-10 with NaOH 2M. The mixture was extracted with
17
18 EtOAc (3 x 20 mL), and the extracts dried over MgSO₄. After evaporation of the
19
20 solvent **30** (58 mg, 67%) was isolated as an off-white solid of mp 136 – 139 °C. ¹H
21
22 NMR (500 MHz, DMSO) δ 10.78 (s, 1H), 7.40 (t, *J* = 5.3 Hz, 1H), 7.23 (d, *J* = 8.7 Hz,
23
24 1H), 7.21 (d, *J* = 2.5 Hz, 1H), 6.94 (d, *J* = 2.4 Hz, 1H), 6.72 (dd, *J* = 8.7, 2.4 Hz, 1H),
25
26 4.19 (s, 2H), 3.70 (s, 3H), 3.18 (qd, *J* = 7.2, 5.3 Hz, 2H), 1.09 (t, *J* = 7.2 Hz, 3H). ¹³C
27
28 NMR (126 MHz, DMSO) δ 168.98, 159.10, 153.54, 131.84, 127.39, 124.74, 112.63,
29
30 111.64, 110.96, 100.72, 55.76, 39.63, 26.47, 14.74. HRMS (ESI⁺): Calcd. for
31
32 C₁₄H₁₆N₄OS (M)⁺ 288.1045, found *m/z* 288.1050. HPLC-MS (230 to 400 nm) 95%
33
34 (*m/z*) [MH⁺] 289.40.
35
36
37
38
39

40
41 **Pharmacology. Assays for human MT₁R and MT₂R subtypes.** 2-
42
43 [¹²⁵I]Iodomelatonin (2200 Ci/mmol) was purchased from NEN (Boston, MA). Other
44
45 drugs and chemicals were purchased from Sigma–Aldrich (Saint Quentin, France).
46

47
48 2-[¹²⁵I]Iodomelatonin binding assay conditions were essentially as previously
49
50 described.⁸⁵ Briefly, binding was initiated by addition of membrane preparations from
51
52 transfected CHO cells stably expressing the human MT₁R or MT₂R diluted in binding
53
54 buffer (50 mM Tris–HCl buffer, pH 7.4, containing 5 mM MgCl₂) to 2-
55
56 [¹²⁵I]iodomelatonin (20 pM) and the tested drug. Non-specific binding was defined in
57
58
59
60

1
2
3 the presence of 1 μM melatonin. After 120 min incubation at 37 $^{\circ}\text{C}$, reaction was
4
5 stopped by rapid filtration through GF/B filters presoaked in 0.5% (v/v)
6
7 polyethylenimine. Filters were washed three times with 1 mL of ice-cold 50 mM Tris–
8
9 HCl buffer, pH 7.4.
10

11
12 Data from the dose-response curves (seven concentrations in duplicate) were
13
14 analysed using the program PRISM (Graph Pad Software Inc., San Diego, CA) to yield
15
16 IC_{50} (inhibitory concentration 50) values. Results are expressed as $K_i = \text{IC}_{50} / (1 +$
17
18 $([L]/K_D))$, where [L] is the concentration of radioligand used in the assay and K_D the
19
20 dissociation constant of the radioligand characterizing the membrane preparation.
21

22
23 [^{35}S]GTP γS binding assay was performed according to published methodology.⁸⁵
24
25 Briefly, membranes from transfected CHO cells expressing MT_1R or MT_2R subtypes
26
27 and compounds were diluted in binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl,
28
29 3 μM GDP, 3 mM MgCl_2 , and 20 $\mu\text{g}/\text{mL}$ saponin). Incubation was started by the
30
31 addition of 0.2 nM [^{35}S]GTP γS to membranes (20 $\mu\text{g}/\text{mL}$) and drugs, and further
32
33 followed for 1 h at rt. Reaction was stopped by rapid filtration through GF/B filters
34
35 followed by three successive washes with ice-cold buffer.
36
37

38
39 Usual levels of [^{35}S]GTP γS binding (expressed in dpm) were for CHO- MT_2
40
41 membranes: 2000 for basal activity, 8000 in the presence of melatonin 1 μM and 180 in
42
43 the presence of GTP γS 10 μM which defined the non-specific binding. Data from the
44
45 dose–response curves (seven concentrations in duplicate) were analyzed by using the
46
47 program PRISM (Graph Pad Software Inc., San Diego, CA) to yield EC_{50} (the effective
48
49 concentration 50%) and E_{max} (maximal effect) for agonists.
50
51

52
53 ***In vitro* Blood–Brain Barrier Permeation Assay (PAMPA).** Prediction of the brain
54
55 penetration was performed using a parallel artificial membrane permeation assay
56
57 (PAMPA-BBB), in a similar manner as previously described.^{43,56,57} Pipetting was done
58
59
60

1
2
3 with a semi-automatic pipettor (CyBi[®]-SELMA) and UV reading with a microplate
4 spectrophotometer (Multiskan Spectrum, Thermo Electron Co.). Commercial drugs,
5 phosphate buffered saline solution at pH 7.4 (PBS), and dodecane were purchased from
6 Sigma, Aldrich, Acros, and Fluka. Millex filter units (PVDF membrane, diameter 25
7 mm, pore size 0.45 μm) were acquired from Millipore. The porcine brain lipid (PBL)
8 was obtained from Avanti Polar Lipids. The donor microplate was a 96-well filter plate
9 (PVDF membrane, pore size 0.45 μm) and the acceptor microplate was an indented 96-
10 well plate, both from Millipore. The acceptor 96-well microplate was filled with 200 μL
11 of PBS:ethanol (70:30) and the filter surface of the donor microplate was impregnated
12 with 4 μL of porcine brain lipid (PBL) in dodecane (20 mg mL^{-1}). Compounds were
13 dissolved in PBS:ethanol (70:30) at 100 $\mu\text{g mL}^{-1}$, filtered through a Millex filter, and
14 then added to the donor wells (200 μL). The donor filter plate was carefully put on the
15 acceptor plate to form a sandwich, which was left undisturbed for 240 min at 25 $^{\circ}\text{C}$.
16 After incubation, the donor plate was carefully removed and the concentration of
17 compounds in the acceptor wells was determined by UV-Vis spectroscopy. Every
18 sample was analyzed at five wavelengths, in four wells and at least in three independent
19 runs, and the results are given as the mean \pm standard deviation. In each experiment, 11
20 quality control standards of known BBB permeability were included to validate the
21 analysis set.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Thermodynamic solubility determination.** The solubility experiments were performed
46 following in part described protocols.^{51,52} UV maximums are extracted from recorded
47 UV-spectra of the compounds in the 270-400 nm range. A 10 mM stock solution of
48 each compound in DMSO is prepared. A calibration line is built by measuring the
49 absorbance at the corresponding maximum wavelength of sequential dilutions of the
50 stock solution in buffer-MeCN (80:20) mixture in a 96-well plate containing 200 μL per
51
52
53
54
55
56
57
58
59
60

1
2
3 point. The buffers employed are: pH 1.2 KCl 45 mM buffer, pH 7.4 phosphate 45 mM
4
5 buffer and pH 9.4 NH₄Cl buffer. In order to validate the calibration line, and exclude
6
7 interferences due to the presence of 5% DMSO, a quality control standard of known
8
9 solubility is employed. The calibration line is accepted if $R^2 > 0.990$, the residual value
10
11 of each point $< 15\%$ and the relative error of the quality control standard $< 15\%$. The
12
13 solubility determination is made as follows: 200 μL of buffer solution are added over
14
15 approximately 1 mg accurately weighted of the tested compound in order to achieve a
16
17 saturated solution. The mixture is kept at rt in an orbital stirrer at 320 rpm for 24 h and
18
19 then centrifuged at 135 rpm for 15 min. 160 μL of the supernatant are transferred to a
20
21 96-well plate and diluted with 40 μL of a buffer-MeCN (80:20) mixture. The solubility
22
23 is calculated by extrapolation to the calibration line within the linearity range and
24
25 expressed in mol/L. The experiments were run in triplicates.
26
27
28

29
30 **Molecular superposition.** Compounds were built with Maestro 9.2⁸⁶ and subjected to
31
32 an energy minimization procedure using the OPLS2005 force field⁸⁷ to a convergence
33
34 threshold of $0.05 \text{ kJ mol}^{-1} \text{ \AA}^{-1}$. Compounds were superposed to the putative bioactive
35
36 conformation of melatonin,⁶ having torsion angles: τ_1 (C3 α -C3-C β -C α) $\approx -78^\circ$; τ_2
37
38 (C3-C β -C α -N) $\approx 180^\circ$; τ_3 (C β -C α -N-CO) $\approx -177^\circ$. Superposed atoms are: the
39
40 methoxy oxygen, C3 α , C5 and C7 of the benzene ring of indoles, and the amide oxygen
41
42 of melatonin that was superposed to the N atom within the five-membered cycles.
43
44

45
46 **Neurogenesis Assays.** *Animals.* Adult (8-12 weeks old) male Wistar rats (n = 6 per
47
48 group), housed in a 12 h light-dark cycle animal facility, were used in this study. All
49
50 procedures with animals were specifically approved by the Ethics Committee for
51
52 Animal Experimentation of the CSIC and carried out in accordance with National
53
54 (normative 1201/2005) and International recommendations (Directive 2010/63 from the
55
56 European Communities Council). Special care was taken to minimize animal suffering.
57
58
59
60

1
2
3 *Neurosphere cultures.* NS were derived from the SGZ of the dentate gyrus of the
4 hippocampus of adult Wistar rats, and induced to proliferate using established passaging
5 methods to achieve optimal cellular expansion according to published protocols.⁵⁴ Rats
6 were decapitated and brains dissected, obtaining the SVZ and the hippocampus as
7 described.⁵⁵ Briefly, cells were seeded into 12-well dishes and cultured in Dubecco's
8 Modified Eagle's Medium (DMEM)/F12 (1:1, Invitrogen) containing 10 ng/mL
9 epidermal growth factor (EGF, Peprotech, London, UK), 10 ng/mL fibroblast growth
10 factor (FGF, Peprotech), and B27 medium (Gibco). After 3 days in culture, primary NS
11 cultures were treated with different compounds for 7 days. To determine the ability of
12 compounds to induce differentiation, then NS were plated onto 100 µg/mL poly-L-
13 lysine-coated coverslips and treated for 48 h in the presence of serum, but in absence of
14 exogenous growth factors.⁸⁸

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29 *Immunocytochemistry.* After treatment, cells were processed for
30 immunocytochemistry with two types of neurogenesis-associated neuronal markers:
31 TuJ1, associated with early stages of neurogenesis, and MAP-2, a marker of neuronal
32 maturation. DAPI staining was used as a nuclear marker. Basal values were obtained
33 under the same conditions, but in the absence of any product. Melatonin (endogenous
34 ligand of the MTRs) and luzindole (melatonergic antagonist) were used as controls. The
35 images were obtained using a Nikon fluorescence microscope 90i that was coupled to a
36 digital camera Qi. The microscope configuration was adjusted to produce the optimum
37 signal-to-noise ratio. The number of TuJ-1 and MAP-2 expressing cells in the NS was
38 estimated as previously described.⁸⁸ Cell numbers were estimated from a total of five
39 NS per condition over three independent experiments.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *Statistical analysis.* The SPSS statistical software package (version 20.0) for
4 Windows (Chicago, IL) was used for the ANOVA (one-way) analyses followed by
5 Student's t post hoc test. A p value ≤ 0.05 was considered to be statistically significant.
6
7
8
9

10 11 **ASSOCIATED CONTENT**

12 **Supporting Information**

13
14
15
16 NMR studies on the tautomerism of hydrogen-bearing azoles **18** and **30**. This material is
17 available free of charge via the Internet at <http://pubs.acs.org>.
18
19
20

21 22 **AUTHOR INFORMATION**

23 **Corresponding Author**

24
25
26
27 *Mailing address: Dr. María Isabel Rodríguez-Franco, Instituto de Química Médica
28 (IQM-CSIC), C/ Juan de la Cierva 3, 28006 Madrid (Spain). Phone: 34-91-5622900.
29 Fax: 34-91-5644853. E-mail: isabelrguez@iqm.csic.es
30
31

32 **Note**

33
34 The authors declare no competing financial interest.
35
36
37
38

39 **ACKNOWLEDGMENTS**

40
41 We gratefully acknowledge the financial support of the Spanish Ministry of
42 Economy and Competitiveness (MINECO, grants SAF2012-31035 and SAF2010-
43 16365), Fundación de Investigación Médica Mutua Madrileña Automovilística (grant
44 AP103952012), and Consejo Superior de Investigaciones Científicas (CSIC, grant PIE-
45 201280E074). The Centro de Investigación Biomédica en Red sobre Enfermedades
46 Neurodegenerativas (CIBERNED) is funded by the Instituto de Salud Carlos III. M.F.R.
47 thanks CSIC for a JAE-Predoctoral Contract and J.A.M.-G. thanks the Postdoctoral
48 Fellowship from CIBERNED. We also acknowledge Dr. Paula Morales for the binding
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 assays on cannabinoid receptors and the National Institute on Mental Health-
4
5 Psychoactive Drug Screening Program (NIMH-PDSP, Contract #HHSN-271-2013-
6
7 00017-C, Dr. Bryan Roth) for binding experiments on serotonin receptors and
8
9 transporter.
10

11 12 13 **ABBREVIATIONS USED**

14
15
16 BBB, blood-brain barrier; CDI, carbonyldiimidazole; CHO, Chinese hamster ovary;
17
18 COSY, homonuclear correlation spectroscopy; DAPI, 4',6-diamidino-2-phenylindole;
19
20 DMAP, dimethylaminopyridine; EC₅₀, half maximal effective concentration; E_{max},
21
22 maximal effect; GPCRs, G-protein-coupled receptors; GTPγS, guanosine 5'-O-(3-
23
24 thiotriphosphate); HMBC, heteronuclear multiple bond correlation; HRMS, high
25
26 resolution mass spectrum; HSQC, heteronuclear single quantum coherence; K_i, binding
27
28 constant; MAP-2, microtubule-associated protein 2; 5-MeO-DMT, 5-methoxy-*N,N*-
29
30 dimethyl-tryptamine; MTRs, melatonin receptors; MT₁R: melatonin receptor subtype 1;
31
32 MT₂R: melatonin receptor subtype 2; NMR, nuclear magnetic resonance; NS,
33
34 neurospheres; SEM, standard error of the mean; SGZ, subgranular zone; SVZ,
35
36 subventricular zone; TEA, triethylamine; THF, tetrahydrofuran; TuJ1, β-tubulin III
37
38 marker
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- (1) Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin--a pleiotropic, orchestrating regulator molecule. *Prog. Neurobiol.* **2011**, *93*, 350-384.
- (2) Zlotos, D. P.; Jockers, R.; Cecon, E.; Rivara, S.; Witt-Enderby, P. A. MT₁ and MT₂ melatonin receptors: ligands, models, oligomers, and therapeutic potential. *J. Med. Chem.* **2014**, *57*, 3161-3185.
- (3) Pala, D.; Lodola, A.; Bedini, A.; Spadoni, G.; Rivara, S. Homology models of melatonin receptors: challenges and recent advances. *Int. J. Mol. Sci.* **2013**, *14*, 8093-8121.
- (4) Mor, M.; Rivara, S.; Pala, D.; Bedini, A.; Spadoni, G.; Tarzia, G. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. *Expert Opin. Ther. Pat.* **2010**, *20*, 1059-1077.
- (5) Pala, D.; Beuming, T.; Sherman, W.; Lodola, A.; Rivara, S.; Mor, M. Structure-based virtual screening of MT₂ melatonin receptor: influence of template choice and structural refinement. *J. Chem. Inf. Model.* **2013**, *53*, 821-835.
- (6) Rivara, S.; Diamantini, G.; Di Giacomo, B.; Lamba, D.; Gatti, G.; Lucini, V.; Pannacci, M.; Mor, M.; Spadoni, G.; Tarzia, G. Reassessing the melatonin pharmacophore—Enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. *Bioorg. Med. Chem.* **2006**, *14*, 3383-3391.
- (7) Jansen, J. M.; Copping, S.; Gruppen, G.; Molinari, E. J.; Dubocovich, M. L.; Grol, C. J. The high affinity melatonin binding site probed with conformationally restricted ligands—I. Pharmacophore and minireceptor models. *Bioorg Med. Chem.* **1996**, *4*, 1321-1332.

- 1
2
3 (8) Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P. r.; Howell, H. E.; Renard,
4 P.; Caignard, D.-H.; Pfeiffer, B.; Delagrange, P. Synthesis and structure-activity
5 relationships of novel naphthalenic and bioisosteric related amidic derivatives as
6 melatonin receptor ligands. *J. Med. Chem.* **1994**, *37*, 3231-3239.
7
8
9
10
11 (9) Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Imai, Y.;
12 Hinuma, S.; Kato, K.; Nishikawa, H.; Hirai, K.; Miyamoto, M.; Ohkawa, S. Synthesis
13 of a novel series of tricyclic indan derivatives as melatonin receptor agonists. *J. Med.*
14 *Chem.* **2002**, *45*, 4222-4239.
15
16
17
18 (10) Tsoinīs, A.; Afroudakis, P. A.; Garratt, P. J.; Bocianowska-Zbrog, A.; Sugden,
19 D. Benzocyclobutane, benzocycloheptane and heptene derivatives as melatonin agonists
20 and antagonists. *ChemMedChem* **2014**, *9*, 2238-2243.
21
22
23
24 (11) Rivara, S.; Lorenzi, S.; Mor, M.; Plazzi, P. V.; Spadoni, G.; Bedini, A.; Tarzia,
25 G. Analysis of structure-activity relationships for MT₂ selective antagonists by
26 melatonin MT₁ and MT₂ receptor models. *J. Med. Chem.* **2005**, *48*, 4049-4060.
27
28
29
30 (12) Dubocovich, M. L. Luzindole (N-0774): a novel melatonin receptor antagonist.
31 *J. Pharmacol. Exp. Ther.* **1988**, *246*, 902-910.
32
33
34
35 (13) Laudon, M.; Zisapel, N. Characterization of central melatonin receptors using
36 ¹²⁵I-melatonin. *FEBS Lett.* **1986**, *197*, 9-12.
37
38
39 (14) Vakkuri, O.; Lämsä, E.; Rahkamaa, E.; Ruotsalainen, H.; Leppäluoto, J.
40 Iodinated melatonin: preparation and characterization of the molecular structure by
41 mass and ¹H NMR spectroscopy. *Anal. Biochem.* **1984**, *142*, 284-289.
42
43
44 (15) Waring, M. J. Lipophilicity in drug discovery. *Expert Opin. Drug Discovery*
45 **2010**, *5*, 235-248.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (16) Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on
4
5 compound developability – are too many aromatic rings a liability in drug design? *Drug*
6
7 *Discovery Today* **2009**, *14*, 1011-1020.
8
9
10 (17) Arnott, J. A.; Planey, S. L. The influence of lipophilicity in drug discovery and
11
12 design. *Expert Opin. Drug Discovery* **2012**, *7*, 863-875.
13
14 (18) Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular
15
16 interactions. *J. Med. Chem.* **2010**, *53*, 5061-5084.
17
18 (19) Leclerc, V.; Fourmaintraux, E.; Depreux, P.; Lesieur, D.; Morgan, P.; Howell,
19
20 H. E.; Renard, P.; Caignard, D. H.; Pfeiffer, B.; Delagrange, P.; Guardiola-Lemaître, B.;
21
22 Andrieux, J. Synthesis and structure-activity relationships of novel naphthalenic and
23
24 bioisosteric related amidic derivatives as melatonin receptor ligands. *Bioorg. Med.*
25
26 *Chem.* **1998**, *6*, 1875-1887.
27
28
29 (20) Willis, G. L. The role of ML-23 and other melatonin analogues in the treatment
30
31 and management of Parkinson's disease. *Drug News Perspect.* **2005**, *18*, 437-444.
32
33
34 (21) Morgan, P. J.; Williams, L. M.; Davidson, G.; Lawson, W.; Howell, E.
35
36 Melatonin receptors on ovine pars tuberalis: characterization and autoradiographicai
37
38 localization. *J. Neuroendocrinol.* **1989**, *1*, 1-4.
39
40 (22) Laudon, M.; Peleg-Shulgman, T. Pyrone-indole derivatives and process for their
41
42 preparation. US 7,635,710 B2 (2009).
43
44 (23) He, P.; Ouyang, X.; Zhou, S.; Yin, W.; Tang, C.; Laudon, M.; Tian, S. A novel
45
46 melatonin agonist Neu-P11 facilitates memory performance and improves cognitive
47
48 impairment in a rat model of Alzheimer' disease. *Horm. Behav.* **2013**, *64*, 1-7.
49
50 (24) Tian, S.-W.; Laudon, M.; Han, L.; Gao, J.; Huang, F.-L.; Yang, Y.-F.; Deng, H.-
51
52 F. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in
53
54 rodent models. *Acta Pharmacol. Sin.* **2010**, *31*, 775-783.
55
56
57
58
59
60

- 1
2
3 (25) Rami, M.; Landagaray, E.; Ettaoussi, M.; Boukhalfa, K.; Caignard, D.-H.;
4 Delagrangé, P.; Berthelot, P.; Yous, S. Novel conformationally constrained analogues
5 of agomelatine as new melatonergic ligands. *Molecules* **2012**, *18*, 154-166.
6
7
8
9 (26) Boström, J.; Hogner, A.; Llinàs, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in
10 medicinal chemistry. *J. Med. Chem.* **2011**, *55*, 1817-1830.
11
12
13 (27) Shen, H.-W.; Jiang, X.-L.; Winter, J. C.; Yu, A.-M. Psychedelic 5-methoxy-*N,N*-
14 dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and
15 pharmacological actions. *Curr. Drug Metab.* **2010**, *11*, 659-666.
16
17
18 (28) Duncan, M. J.; Takahashi, J. S.; Dubocovich, M. L. 2-[¹²⁵I]Iodomelatonin
19 binding sites in hamster brain membranes: pharmacological characteristics and regional
20 distribution. *Endocrinology* **1988**, *122*, 1825-1833.
21
22
23 (29) Basarab, G. S.; Manchester, J. I.; Bist, S.; Boriack-Sjodin, P. A.; Dangel, B.;
24 Illingworth, R.; Sherer, B. A.; Sriram, S.; Uria-Nickelsen, M.; Eakin, A. E. Fragment-
25 to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual
26 targeting type II topoisomerase inhibiting antibacterial agents. *J. Med. Chem.* **2002**, *56*,
27 8712-8735.
28
29
30 (30) Ramírez-Rodríguez, G.; Klempin, F.; Babu, H.; Benítez-King, G.; Kempermann,
31 G. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice.
32 *Neuropsychopharmacology* **2009**, *34*, 2180-2191.
33
34
35 (31) Kempermann, G.; Jessberger, S.; Steiner, B.; Kronenberg, G. Milestones of
36 neuronal development in the adult hippocampus. *Trends Neurosci.* **2004**, *27*, 447-452.
37
38
39 (32) Mongiat, L. A.; Schinder, A. F. Neuroscience. A price to pay for adult
40 neurogenesis. *Science* **2014**, *344*, 594-595.
41
42
43 (33) Duman, R. S.; Malberg, J.; Nakagawa, S. Regulation of adult neurogenesis by
44 psychotropic drugs and stress. *J. Pharmacol. Exp. Ther.* **2001**, *299*, 401-407.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (34) Rolando, C.; Taylor, V. Neural stem cell of the hippocampus: development,
4 physiology regulation, and dysfunction in disease. *Curr. Top. Dev. Biol.* **2014**, *107*,
5 183-206.
6
7
8
9
10 (35) Abdipranoto, A.; Wu, S.; Stayte, S.; Vissel, B. The role of neurogenesis in
11 neurodegenerative diseases and its implications for therapeutic development. *CNS*
12 *Neurol. Disord. Drug Targets* **2008**, *7*, 187-210.
13
14
15
16 (36) Iguichi, H.; Kato, K. I.; Ibayashi, H. Age-dependent reduction in serum
17 melatonin concentrations in healthy human subjects. *J. Clin. Endocrinol. Metab.* **1982**,
18 *55*, 27-29.
19
20
21
22
23 (37) Ramírez-Rodríguez, G.; Vega-Rivera, N. M.; Benítez-King, G.; Castro-García,
24 M.; Ortiz-López, L. Melatonin supplementation delays the decline of adult hippocampal
25 neurogenesis during normal aging of mice. *Neurosci. Lett.* **2012**, *530*, 53-58.
26
27
28
29
30 (38) López, L. C.; Escames, G.; López, A.; García, J. A.; Doerrier, C.; Acuña-
31 Castroviejo, D. Melatonin, neurogenesis, and aging brain. *Open Neuroendocrinol. J.*
32 **2010**, *3*, 121-133.
33
34
35
36 (39) Poeggeler, B. Melatonin, aging, and age-related diseases. *Endocrine* **2005**, *27*,
37 201-212.
38
39
40
41 (40) Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-
42 Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for
43 Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant
44 properties. *J. Med. Chem.* **2006**, *49*, 459-462.
45
46
47
48
49 (41) Fernández-Bachiller, M. I.; Pérez, C.; Campillo, N. E.; Páez, J. A.; González-
50 Muñoz, G. C.; Usán, P.; García-Palomero, E.; López, M. G.; Villarroya, M.; García, A.
51 G.; Martínez, A.; Rodríguez-Franco, M. I. Tacrine-melatonin hybrids as multifunctional
52
53
54
55
56
57
58
59
60

- agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. *ChemMedChem* **2009**, *4*, 828-841.
- (42) Spuch, C.; Antequera, D.; Fernández-Bachiller, M. I.; Rodríguez-Franco, M. I.; Carro, E. A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease. *Neurotox. Res.* **2010**, *17*, 421-431.
- (43) López-Iglesias, B.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Romero, A.; López, M. G.; Villarroja, M.; Conde, S.; Rodríguez-Franco, M. I. New melatonin-*N,N*-dibenzyl(*N*-methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. *J. Med. Chem.* **2014**, *57*, 3773-3785.
- (44) de la Fuente Revenga, M.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Caignard, D. H.; Yáñez, M.; Gamo, A. M.; Rodríguez-Franco, M. I. Neurogenic potential assessment and pharmacological characterization of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (pinoline) and melatonin-pinoline hybrids. *ACS Chem. Neurosci.* **2015**, *6*, 800-810.
- (45) Verniest, G.; England, D.; De Kimpe, N.; Padwa, A. Synthesis of substituted β -carbolines via gold(III)-catalyzed cycloisomerization of *N*-propargylamides. *Tetrahedron* **2010**, *66*, 1496-1502.
- (46) Verniest, G.; Padwa, A. Gold- and silver-mediated cycloisomerizations of *N*-propargylamides. *Org. Lett.* **2008**, *10*, 4379-4382.
- (47) Kumar, V.; Kaur, S.; Kumar, S. $ZrCl_4$ catalyzed highly selective and efficient Michael addition of heterocyclic enamines with α,β -unsaturated olefins. *Tetrahedron Lett.* **2006**, *47*, 7001-7005.
- (48) Saitoh, M.; Kunitomo, J.; Kimura, E.; Iwashita, H.; Uno, Y.; Onishi, T.; Uchiyama, N.; Kawamoto, T.; Tanaka, T.; Mol, C. D.; Dougan, D. R.; Textor, G. P.;

1
2
3 Snell, G. P.; Takizawa, M.; Itoh, F.; Kori, M. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-
4 benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen
5 synthase kinase-3 β with good brain permeability. *J. Med. Chem.* **2009**, *52*, 6270-6286.

6
7
8
9 (49) Zoumpoulakis, P.; Camoutsis, C.; Pairas, G.; Soković, M.; Glamočlija, J.;
10 Potamitis, C.; Pitsas, A. Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-
11 thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents.
12 Biological evaluation and conformational analysis studies. *Bioorg. Med. Chem.* **2012**,
13 *20*, 1569-1583.

14
15
16 (50) Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.;
17 Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.-P.; Malpoux, B.;
18 Guillaumet, G.; Lesieur, D. I.; Lefoulon, F.; Renard, P.; Delagrangé, P.; Boutin, J. A.
19 New selective ligands of human cloned melatonin MT₁ and MT₂ receptors. *Naunyn-
20 Schmiedebergs Arch. Pharmacol.* **2003**, *367*, 553-561.

21
22 (51) Bard, B.; Martel, S.; Carrupt, P. A. High throughput UV method for the
23 estimation of thermodynamic solubility and the determination of the solubility in
24 biorelevant media. *Eur. J. Pharm. Sci.* **2008**, *33*, 230-240.

25
26 (52) Tan, H.; Semin, D.; Wacker, M.; Cheetham, J. An automated screening assay for
27 determination of aqueous equilibrium solubility enabling SPR study during drug lead
28 optimization. *J. Lab. Autom.* **2005**, *10*, 364-373.

29
30 (53) Zubets, I. V.; Vergizov, S. N.; Yakovlev, S. I.; V'Yunov, K. A. Basicity and
31 mechanism of transmission of electronic effects of substituents in the series of 2-amino-
32 5-aryl-1,3,4-thiadiazoles. *Chem. Heterocycl. Compd.* **1987**, *23*, 225-228.

33
34 (54) Ferrón, S. R.; Andreu-Agulló, C.; Mira, H.; Sánchez, P.; Marqués-Torrejón, M.
35 A.; Fariñas, I. A combined *ex/in vivo* assay to detect effects of exogenously added
36 factors in neural stem cells. *Nat. Protoc.* **2007**, *2*, 849-859.

- 1
2
3 (55) Morales-García, J. A.; Luna-Medina, R.; Alfaro-Cervello, C.; Cortes-Canteli,
4 M.; Santos, A.; García-Verdugo, J. M.; Pérez-Castillo, A. Peroxisome proliferator-
5 activated receptor gamma ligands regulate neural stem cell proliferation and
6
7 differentiation *in vitro* and *in vivo*. *Glia* **2011**, *59*, 293-307.
8
9
10
11 (56) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput
12 artificial membrane permeability assay for blood–brain barrier. *Eur. J. Med. Chem.*
13 **2003**, *38*, 223-232.
14
15
16 (57) Fernández-Bachiller, M. I.; Pérez, C.; Monjas, L.; Rademann, J.; Rodríguez-
17 Franco, M. I. New tacrine-4-oxo-4*H*-chromene hybrids as multifunctional agents for the
18 treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-
19 reducing properties. *J. Med. Chem.* **2012**, *55*, 1303-1317.
20
21
22 (58) Conway, S.; Canning, S. J.; Howell, H. E.; Mowat, E. S.; Barrett, P.; Drew, J. E.;
23 Delagrangé, P.; Lesieur, D.; Morgan, P. J. Characterisation of human melatonin MT₁
24 and MT₂ receptors by CRE-luciferase reporter assay. *Eur. J. Pharmacol.* **2000**, *390*, 15-
25 24.
26
27 (59) Bedini, A.; Lucarini, S.; Spadoni, G.; Tarzia, G.; Scaglione, F.; Dugnani, S.;
28 Pannacci, M.; Lucini, V.; Carmi, C.; Pala, D.; Rivara, S.; Mor, M. Toward the definition
29 of stereochemical requirements for MT₂-selective antagonists and partial agonists by
30 studying 4-phenyl-2-propionamidotetralin derivatives. *J. Med. Chem.* **2011**, *54*, 8362-
31 8372.
32
33 (60) Mattson, R. J.; Catt, J. D.; Keavy, D.; Sloan, C. P.; Epperson, J.; Gao, Q.;
34 Hodges, D. B.; Iben, L.; Mahle, C. D.; Ryan, E.; Yocca, F. D. Indanyl piperazines as
35 melatonergic MT₂ selective agents. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1199-1202.
36
37 (61) Durieux, S.; Chanu, A.; Bochu, C.; Audinot, V.; Coumailleau, S.; Boutin, J. A.;
38 Delagrangé, P.; Caignard, D.-H.; Bennejean, C.; Renard, P.; Lesieur, D.; Berthelot, P.;
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Yous, S. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new
4
5 selective MT₂ melatoninerpic ligands. Part II. *Bioorg. Med. Chem.* **2009**, *17*, 2963-
6
7 2974.
8
9 (62) Shida, C. S.; Castrucci, A. M. L.; Lamy-Freund, M. T. High melatonin solubility
10
11 in aqueous medium. *J. Pineal Res.* **1994**, *16*, 198-201.
12
13 (63) Csuk, R.; von Scholz, Y. Synthesis of racemic carbocyclic cyclopropanoid
14
15 nucleoside analogues. *Tetrahedron* **1995**, *51*, 7193-7206.
16
17 (64) O'Neil, M. J., The Merck Index - An Encyclopedia of Chemicals, Drugs, and
18
19 Biologicals (14th Edition - Version 14.9). Merck Sharp & Dohme Corp., a subsidiary of
20
21 Merck & Co., Inc.: 2012.
22
23 (65) Glennon, R. A.; Titeler, M.; McKenney, J. D. Evidence for 5-HT₂ involvement
24
25 in the mechanism of action of hallucinogenic agents. *Life Sci.* **1984**, *35*, 2505-2511.
26
27 (66) Nonaka, R.; Nagai, F.; Ogata, A.; Satoh, K. In vitro screening of psychoactive
28
29 drugs by [(35)S]GTPgammaS binding in rat brain membranes. *Biol. Pharm. Bull.* **2007**,
30
31 *30*, 2328-2333.
32
33 (67) Cagnacci, A.; Krauchi, K.; Wirz-Justice, A.; Volpe, A. Homeostatic *versus*
34
35 circadian effects of melatonin on core body temperature in humans. *J. Biol. Rhythms*
36
37 **1997**, *12*, 509-517.
38
39 (68) Glennon, R. A.; Dukat, M.; Grella, B.; Hong, S.; Costantino, L.; Teitler, M.;
40
41 Smith, C.; Egan, C.; Davis, K.; Mattson, M. V. Binding of beta-carbolines and related
42
43 agents at serotonin (5-HT₂ and 5-HT_{1A}), dopamine (D₂) and benzodiazepine receptors.
44
45 *Drug Alcohol Depend.* **2000**, *60*, 121-132.
46
47 (69) Lange, C.; Mix, E.; Frahm, J.; Glass, A.; Müller, J.; Schmitt, O.; Schmöle, A.-
48
49 C.; Klemm, K.; Ortinau, S.; Hübner, R.; Frech, M. J.; Wree, A.; Rolfs, A. Small
50
51
52
53
54
55
56
57
58
59
60

1
2
3 molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells.

4
5 *Neurosci. Lett.* **2011**, *488*, 36-40.

6
7 (70) Jiang, W.; Zhang, Y.; Xiao, L.; Van Cleemput, J.; Ji, S.-P.; Bai, G.; Zhang, X.

8
9 Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce
10
11 anxiolytic- and antidepressant-like effects. *J. Clin. Invest.* **2005**, *115*, 3104-3116.

12
13 (71) Banasr, M.; Hery, M.; Printemps, R.; Daszuta, A. Serotonin-induced increases in
14
15 adult cell proliferation and neurogenesis are mediated through different and common 5-
16
17 HT receptor subtypes in the dentate gyrus and the subventricular zone.

18
19 *Neuropsychopharmacology* **2004**, *29*, 450-460.

20
21 (72) Benninghoff, J.; van der Ven, A.; Schloesser, R. J.; Moessner, R.; Moller, H. J.;

22
23 Rujescu, D. The complex role of the serotonin transporter in adult neurogenesis and
24
25 neuroplasticity. A critical review. *World J. Biol. Psychiatry* **2012**, *13*, 240-247.

26
27 (73) Yu, S.; Levi, L.; Siegel, R.; Noy, N. Retinoic acid induces neurogenesis by
28
29 activating both retinoic acid receptors (RARs) and peroxisome proliferator-activated
30
31 receptor β/δ (PPAR β/δ). *J. Biol. Chem.* **2012**, *287*, 42195-42205.

32
33 (74) Hardeland, R. Melatonin: signaling mechanisms of a pleiotropic agent.

34
35 *Biofactors* **2009**, *35*, 183-192.

36
37 (75) Masana, M. I.; Dubocovich, M. L. Melatonin receptor signaling: finding the path
38
39 through the dark. *Sci. STKE* **2001**, pe39.

40
41 (76) Musshoff, U.; Riewenherm, D.; Berger, E.; Fauteck, J.-D.; Speckmann, E.-J.

42
43 Melatonin receptors in rat hippocampus: molecular and functional investigations.

44
45 *Hippocampus* **2002**, *12*, 165-173.

46
47 (77) Ferguson, F. M.; Fedorov, O.; Chaikuad, A.; Philpott, M.; Muniz, J. R. C.;

48
49 Felletar, I.; von Delft, F.; Heightman, T.; Knapp, S.; Abell, C.; Ciulli, A. Targeting low-

1
2
3 druggability bromodomains: Fragment based screening and inhibitor design against the
4
5 BAZ2B bromodomain. *J. Med. Chem.* **2013**, *56*, 10183-10187.

6
7 (78) The effect of compounds **16** and **19** on impedance (MT₁) and cAMP levels
8
9 (MT₂) was measured and compared to that of melatonin in Chinese Hamster Ovary cells
10
11 expressing human recombinant MT receptors by cellular dielectric spectroscopy for
12
13 MT₁ and in a homogeneous time resolved fluorescent assay for MT₂ by CEREP. The
14
15 corresponding protocols can be found in the company website: www.cerep.fr.

16
17 (79) Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.;
18
19 Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K.
20
21 J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of
22
23 quantitative pharmacology. *J. Pharmacol. Exp. Ther.* **2007**, *320*, 1-13.

24
25 (80) Rodríguez-Franco, M. I.; de la Fuente Revenga, M.; Pérez, C.; Pérez-Castillo,
26
27 A.; Morales-García, J. A.; Alonso-Gil, S. Neurogenic compounds comprising melatonin
28
29 and the efficacy thereof in *in vivo* experiments for use in the treatment of diseases of the
30
31 nervous system. WO 2014154925 A1, 2014.


32
33 (81) Neuville, P.; Schann, S. Melatonin derivatives and their use for treating
34
35 neurological dysfunctions. WO 2004085392 A1, 2004.

36
37 (82) Boularot, A.; Giglione, C.; Petit, S.; Duroc, Y.; Alves de Sousa, R.; Larue, V.;
38
39 Cresteil, T.; Dardel, F.; Artaud, I.; Meinnel, T. Discovery and refinement of a new
40
41 structural class of potent peptide deformylase inhibitors. *J. Med. Chem.* **2007**, *50*, 10-20.

42
43 (83) Rensen, M. Cyclisation of 1-Methyl-5-methoxyindole-3-propionic Acid. *Bull.*
44
45 *Soc. Chim. Belges* **1959**, *68*, 258-269.

46
47 (84) Piotrowska, H.; Serafin, B.; Wejroch-Matacz, K. New amidine derivatives of
48
49 indole. *Pol. J. Pharmacol. Pharm.* **1975**, *27*, 297-303.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (85) Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.;
4
5 Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J. P.; Malpoux, B.;
6
7 Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrangé, P.; Boutin, J. A. New
8
9 selective ligands of human cloned melatonin MT₁ and MT₂ receptors. *Naunyn-*
10
11 *Schmiedeberg's Arch. Pharmacol.* **2003**, *367*, 553-561.
12
13
14 (86) Fukatsu, K.; Uchikawa, O.; Kawada, M.; Yamano, T.; Yamashita, M.; Kato, K.;
15
16 Hirai, K.; Hinuma, S.; Miyamoto, M.; Ohkawa, S. Synthesis of a Novel Series of
17
18 Benzocycloalkene Derivatives as Melatonin Receptor Agonists. *J. Med. Chem.* **2002**,
19
20 *45*, 4212-4221.
21
22
23 (87) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of
24
25 the OPLS all-atom force field on conformational energetics and properties of organic
26
27 liquids. *J. Am. Chem. Soc.* **1996**, *118*, 11225–11236.
28
29
30 (88) Morales-García, J. A.; Luna-Medina, R.; Alonso-Gil, S.; Sanz-Sancristóbal, M.;
31
32 Palomo, V.; Gil, C.; Santos, A.; Martínez, A.; Pérez-Castillo, A. Glycogen synthase
33
34 kinase 3 inhibition promotes adult hippocampal neurogenesis *in vitro* and *in vivo*. *ACS*
35
36 *Chem. Neurosci.* **2012**, *3*, 963-971.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



TOC graphic
304x171mm (96 x 96 DPI)




Figure 1. Melatonergic drugs on the market and other selected melatonergic ligands.
167x114mm (300 x 300 DPI)





Figure 2. Illustration showing the replacement of the acetamido moiety of melatonin carried out in this work.
105x102mm (300 x 300 DPI)



45 Figure 3. Expression of TuJ1 (green) and MAP-2 (red) in cultured SGZ-derived neurospheres in the presence
46 of different compounds at 10 μ M. DAPI (blue) was used as a nuclear marker. Scale bar, 200 μ m.
47 128x147mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Effect of luzindole (10 μ M) on the expression of TuJ1 (green) and MAP-2 (red) promoted by melatonin, 16, and 19 at 10 μ M in SGZ-derived neurospheres. DAPI (blue) was used as a nuclear marker.

Scale bar, 200 μ m.

130x198mm (300 x 300 DPI)




Figure 5. (Top) Dose-response (μM) effect of compound 16 on the expression of TuJ1 (green) and MAP-2 (red) in SGZ-derived neurospheres. DAPI (blue) was used as a nuclear marker. Scale bar, $200\mu\text{m}$. (Bottom) Number of TuJ1+ and MAP-2+ expressing cells in neurospheres is shown and expressed as the mean \pm SD.

** $p \leq 0.01$; *** $p \leq 0.001$.
106x143mm (300 x 300 DPI)




Figure 6. Superposition of melatonin (yellow carbons) in its putative bioactive conformation6 and 6 (green carbons).

423x529mm (96 x 96 DPI)






Figure 7. Compounds 15 (orange carbons), 16 (gray carbons) (panel a) and compound 19 (green carbons) (panel b) superposed on melatonin (yellow carbons).
1005x550mm (96 x 96 DPI)



32 Figure 8. Schematic representation of the functional selectivity hypothesis of melatonin-azole derivatives at
33 MT receptors. (Panel a) Melatonin, the reference and native ligand, binds to melatonergic receptors
34 coupled to G-proteins, that upon activation bind [³⁵S]GTP_γS. The amount of G-protein activated is taken
35 arbitrarily as 100%. The size and names of the G-proteins are fictional and represent the relative population of certain
36 activated G-protein isoforms. (Panel b) The low binding of [³⁵S]GTP_γS upon binding of melatonin-azole
37 derivatives to melatonergic receptors could indicate the preferential activation of certain populations of MTn-
38 Gn, and subsequently, of their corresponding signaling pathways.

140x103mm (300 x 300 DPI)



Scheme 1. Reagents and conditions: (a) CDI, CH₂Cl₂, propargylamine or allylamine, rt; (b) AuCl₃, CH₂Cl₂, N₂, rt; (c) H₂SO₄ (cat.), EtOH, reflux; (d) ethylacrylate, ZrCl₄ (anh.), CH₂Cl₂, N₂, rt; (e) acetamidoxime, NaH, THF, mol. sieves, 80 °C; (f) hydrazine hydrate, 150 °C (mw), 45 min; (g) orthoester, AcOH (cat.), 125 °C (mw), 1 h; (h) compounds with X = O: CDI, TEA, THF, 100 °C (mw), 10 min; (i) compounds with X = S: CS₂, EtOH, KOH (aq.), 150 °C (mw), 10 min; (j) intermediates with X = O and R = Me: MeNCO, EtOH, rt; (k) intermediates with X = S and R = Et: EtSCN, EtOH, rt; (l) NaOH (aq.), EtOH, 100 °C (mw), 15 min; (m) POCl₃, rt.

170x167mm (300 x 300 DPI)